var title_f14_61_15312="Method of penile self injection";
var content_f14_61_15312=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F60326&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F60326&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 570px\">",
"   <div class=\"ttl\">",
"    Method of administering intrapenile injection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 550px; height: 379px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    To be fully effective, the medications must be injected directly into one of the penile erectile bodies, the corporus cavernosum. The medication will diffuse over to the other side of the penis so that symmetrical erection is achieved. A cross section of the penis shows the relationship of the site of injection to the corpora cavernosae.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_61_15312=[""].join("\n");
var outline_f14_61_15312=null;
var title_f14_61_15313="Inguinal region";
var content_f14_61_15313=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F63080&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F63080&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Inguinal region",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 416px; height: 440px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_61_15313=[""].join("\n");
var outline_f14_61_15313=null;
var title_f14_61_15314="Boston Sci Res Clips endosc";
var content_f14_61_15314=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F67534&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F67534&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Treatment of a bleeding gastric ulcer with endoclips",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 323px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Treatment of an actively bleeding gastric ulcer using Boston Scientific Resolution Clips.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dennis M. Jensen, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_61_15314=[""].join("\n");
var outline_f14_61_15314=null;
var title_f14_61_15315="Early repair in osteomyelitis";
var content_f14_61_15315=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F62981&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F62981&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Early repair in acute osteomyelitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 308px; height: 227px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph in acute osteomyelitis of the tibial articular apparatus. The presence of whorls of chondrocytes (blue arrows) indicates early tissue repair in which multinucleated osteoclasts (black arrows) are actively remodeling the subchondral region. Bone (white arrow) has replaced the mature lamellar structure and the medullary spaces are largely filled with inflammatory cells and fibrin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jon Mader, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_61_15315=[""].join("\n");
var outline_f14_61_15315=null;
var title_f14_61_15316="Proximal tibia intraosseous site";
var content_f14_61_15316=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F67266&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F67266&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 530px\">",
"   <div class=\"ttl\">",
"    Proximal tibial intraosseous access site",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 510px; height: 459px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Entry site at the proximal tibia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Hodge Dee III. Intraosseous infusion. In: Textbook of Pediatric Emergency Procedures, 2nd ed, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_61_15316=[""].join("\n");
var outline_f14_61_15316=null;
var title_f14_61_15317="Amitriptyline and chlordiazepoxide: Patient drug information";
var content_f14_61_15317=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Amitriptyline and chlordiazepoxide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/44/41671?source=see_link\">",
"     see \"Amitriptyline and chlordiazepoxide: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10018399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700557",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Children and teens who take this drug may be at a greater risk of having thoughts or actions of suicide. Adults may also be at risk. The risk may be greater in people who have had these thoughts or actions in the past. Watch people who take this drug closely. Call the doctor right away if signs like low mood (depression), nervousness, restlessness, grouchiness, panic attacks, or changes in mood or actions are new or worse. Call the doctor right away if any thoughts or actions of suicide occur.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10018401\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691808",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat low mood (depression).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691728",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat anxiety.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10018400\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701500",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to amitriptyline, chlordiazepoxide, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703572",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Glaucoma or recent heart attack.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10018405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697302",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor. You may be more sensitive to this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697796",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of cavities.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10018406\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10018408\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698706",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are planning to harm yourself or the want to harm yourself gets worse.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10018403\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10018404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10018409\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10018410\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11462 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-60.18.131.125-8B92F8E3C2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_61_15317=[""].join("\n");
var outline_f14_61_15317=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018399\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018401\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018400\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018405\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018406\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018408\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018403\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018404\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018409\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018410\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?40/44/41671?source=related_link\">",
"      Amitriptyline and chlordiazepoxide: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_61_15318="Zaleplon: Drug information";
var content_f14_61_15318=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Zaleplon: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?6/51/6965?source=see_link\">",
"    see \"Zaleplon: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F235597\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Sonata&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F235622\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Hypnotic, Miscellaneous",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F235600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Insomnia (short-term use):",
"     </b>",
"     Oral: 10 mg at bedtime (range: 5-20 mg)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F235601\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reduce dose to 5 mg at bedtime; maximum: 10 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F235602\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No adjustment for mild-to-moderate renal impairment; use in severe renal impairment has not been adequately studied.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F235603\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Mild-to-moderate impairment: 5 mg; not recommended for use in patients with severe hepatic impairment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F235572\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 5 mg, 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sonata&reg;: 5 mg, 10 mg [contains tartrazine]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F235557\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F235624\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-IV",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7875059\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at file://labeling.pfizer.com/ShowLabeling.aspx?id=710, must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F235575\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Immediately before bedtime or when the patient is in bed and cannot fall asleep",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F235573\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Short-term (7-10 days) treatment of insomnia (has been demonstrated to be effective for up to 5 weeks in controlled trial)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F7913944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Sonata&reg; may be confused with Soriatane&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Zaleplon may be confused with Zelapar&reg;, Zemplar&reg;, zolpidem, ZyPREXA&reg; Zydis&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F235620\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Central nervous system: Headache (30% to 42%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Chest pain (&ge;1%), peripheral edema (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (7% to 9%), somnolence (5% to 6%), amnesia (2% to 4%), depersonalization (&lt;1% to 2%), hypoesthesia (&lt;1% to 2%), malaise (&lt;1% to 2%), abnormal thinking (&ge;1%), anxiety (&ge;1%), depression (&ge;1%), fever (&ge;1%), migraine (&ge;1%), nervousness (&ge;1%), confusion (&le;1%), hallucination (&le;1%), vertigo (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus (&ge;1%), rash (&ge;1%), photosensitivity reaction (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Dysmenorrhea (3% to 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (6% to 8%), abdominal pain (6%), anorexia (&lt;1% to 2%), constipation (&ge;1%), dyspepsia (&ge;1%), taste perversion (&ge;1%), xerostomia (&ge;1%), colitis (up to 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (5% to 7%), paresthesia (3%), tremor (2%), arthralgia (&ge;1%), arthritis (&ge;1%), back pain (&ge;1%), myalgia (&ge;1%), hypertonia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Eye pain (3% to 4%), abnormal vision (&lt;1% to 2%), conjunctivitis (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Hyperacusis (1% to 2%), ear pain (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Bronchitis (&ge;1%), epistaxis (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Parosmia (&lt;1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Abnormal accommodation, abnormal gait, agitation, alopecia, ALT increased, anaphylactic/anaphylactoid reactions (including severe reactions, nightmares and paradoxical drug reaction), anemia, angina, apathy, aphthous stomatitis, apnea, appetite (increased), arthrosis, AST increased, asthma, ataxia, bigeminy, biliary pain, bilirubinemia, bleeding gums, blepharitis, breast pain, bruxism, bundle branch block, bursitis, cardiospasm, cataracts, cerebral ischemia, cholelithiasis, circumoral paresthesia, CNS stimulation, complex sleep-related behavior (sleep-driving, cooking or eating food, making phone calls), contact dermatitis, corneal erosion, cyanosis, cystitis, deafness, delayed menstrual period, delusions, diabetes mellitus, diplopia, dry eyes, duodenal ulcer, dysphagia, dysarthria, dyspnea, dystonia, dysuria, ecchymosis, edema, emotional lability, eosinophilia, eructation, esophagitis, euphoria, eye hemorrhage, facial paralysis, gastritis, gastroenteritis, generalized edema, glaucoma, gingivitis, glossitis, goiter, gout, hangover effect, hematuria, hypercholesteremia, hyperesthesia, hyper-/hypoglycemia, hyper-/hypokinesia, hyper-/hypotension, hyperuricemia, hyperventilation, hypothyroidism, hypotonia, incontinence, incoordination, insomnia, intestinal obstruction, ketosis, kidney calculi, kidney pain, leukocytosis, leukorrhea, lymphocytosis, liver function tests (abnormal), lymphadenopathy, maculopapular rash, melanosis, melena, menorrhagia, metrorrhagia, myasthenia, myoclonus, myositis, neck rigidity, neuralgia, neuropathy, nystagmus, orthostatic hypotension, osteoporosis, palpitation, peptic ulcer, pericardial effusion, photophobia, pleural effusion, pneumonia, psychomotor retardation, ptosis, pulmonary embolus, purpura, pustular rash, rash, rectal bleeding, reflexes decreased/increased, retinal detachment, salivation (increased), sinus bradycardia, skin discoloration, skin hypertrophy, sleep talking, sleep walking, slurred speech, sputum increased, stupor, substernal chest pain, syncope, sweating, taste loss, tenosynovitis, thirst, thrombophlebitis, tinnitus, tongue discoloration, tongue edema, trismus, ulcerative stomatitis, urethritis, urinary frequency, urinary retention, urinary urgency, urticaria, vaginal bleeding, vaginitis, vasodilation, ventricular tachycardia, ventricular extrasystoles, vesiculobullous rash, visual field defect, weight gain/loss",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F235578\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to zaleplon or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F235561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abnormal thinking/behavioral changes: Hypnotics/sedatives have been associated with abnormal thinking and behavior changes including decreased inhibition, aggression, bizarre behavior, agitation, hallucinations, and depersonalization. These changes may occur unpredictably and may indicate previously unrecognized psychiatric disorders; evaluate appropriately.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression impairing physical and mental capabilities; patients must be cautioned about performing tasks which require mental alertness (operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Postmarketing studies have indicated that the use of hypnotic/sedative agents for sleep has been associated with hypersensitivity reactions including anaphylaxis as well as angioedema.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sleep-related activities: An increased risk for hazardous sleep-related activities such as sleep-driving, cooking and eating food, and making phone calls while asleep have been noted; amnesia may also occur. Evaluation is recommended in patients who report any sleep-related episodes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Depression: Use with caution in patients with depression; worsening of depression, including suicidal ideation, has been reported with the use of hypnotics. Intentional overdose may be an issue in this population; prescribe least amount of medication needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug abuse: Use with caution in patients with a history of drug dependence.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; dosage adjustment recommended in mild-to-moderate impairment and avoid use in severe impairment. Use is not recommended in patients with severe impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use with caution in patients with respiratory compromise, COPD, or sleep apnea.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depressants/psychoactive medications: Use with caution in patients receiving other CNS depressants or psychoactive medication; effects with other sedative drugs or ethanol may be potentiated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; dosage adjustment recommended. Avoid chronic use (&gt;90 days) in older adults; adverse events, including delirium, falls, fractures, has been observed with nonbenzodiazepine hypnotic use in the elderly similar to events observed with benzodiazepines. Data suggests improvements in sleep duration and latency are minimal (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tartrazine (FDC yellow #5): Capsules contain tartrazine; avoid in patients with sensitivity (caution in patients with asthma).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Symptomatic treatment of insomnia should be initiated only after careful evaluation of potential causes of sleep disturbance. Failure of sleep disturbance to resolve after 7-10 days may indicate psychiatric and/or medical illness.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Rapid onset: Because of the rapid onset of action, administer immediately prior to bedtime or after the patient has gone to bed and is having difficulty falling asleep.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal: Abrupt discontinuance may lead to withdrawal symptoms.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F235616\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F235566\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May decrease the metabolism of Zaleplon.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Flumazenil: May diminish the sedative effect of Hypnotics (Nonbenzodiazepine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Zaleplon.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: Hypnotics (Nonbenzodiazepine) may enhance the CNS depressant effect of Sodium Oxybate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F235593\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Ethanol may increase CNS depression. Management: Avoid or limit use of ethanol and monitor for increased effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: High-fat meals prolong absorption; delay T",
"     <sub>",
"      max",
"     </sub>",
"     by 2 hours, and reduce C",
"     <sub>",
"      max",
"     </sub>",
"     by 35%. Management: Avoid taking after a high-fat meal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease zaleplon levels. Some herbal medications may increase CNS depression. Management: Avoid St John's wort, valerian, kava kava, and gotu kola.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F235568\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F235581\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal reproduction studies. Adverse effects, including stillbirth, postnatal mortality, and decreased growth and physical development, were observed near the end of gestation. A small study of pregnant women did not show an increased risk of teratogenic effects when used early in pregnancy (Wiker, 2011). Use during pregnancy  is not recommended by the manufacturer.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F235606\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F14642029\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Zaleplon is excreted in human milk with the highest concentration ~1 hour after administration; therefore, the manufacturer does not recommended use while breast-feeding.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F5648904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid taking with or after a heavy, high-fat meal; reduces absorption.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F235580\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Sonata Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $571.12",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $586.68",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Zaleplon Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $364.64",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $374.58",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F235582\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Andante (RU);",
"     </li>",
"     <li>",
"      Demare (TW);",
"     </li>",
"     <li>",
"      Hegon (AR);",
"     </li>",
"     <li>",
"      Hipnodem (AR);",
"     </li>",
"     <li>",
"      Noctiplon (CN);",
"     </li>",
"     <li>",
"      Onsleep (TW);",
"     </li>",
"     <li>",
"      Plenidon (CN, PE);",
"     </li>",
"     <li>",
"      Prox (UY);",
"     </li>",
"     <li>",
"      Siweitan (CL);",
"     </li>",
"     <li>",
"      Solmin (TW);",
"     </li>",
"     <li>",
"      Sonata (AT, AU, BE, BG, BR, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HN, IE, IT, MT, MX, NL, NO, NZ, PL, PT, SE, SK, TR);",
"     </li>",
"     <li>",
"      Sotalon (TW);",
"     </li>",
"     <li>",
"      Zaplon (IN);",
"     </li>",
"     <li>",
"      Zerene (BG, ES, FI, NO)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F235560\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Zaleplon is unrelated to benzodiazepines, barbiturates, or other hypnotics. However, it interacts with the benzodiazepine GABA receptor complex. Nonclinical studies have shown that it binds selectively to the brain omega-1 receptor situated on the alpha subunit of the GABA-A receptor complex.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F235577\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid and almost complete; high-fat meal delays absorption",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : ~1.4 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~45% to 75%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensive, primarily via aldehyde oxidase to form 5-oxo-zaleplon and, to a lesser extent, by CYP3A4 to desethylzaleplon; all metabolites are pharmacologically inactive",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: ~30%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (~70% primarily metabolites, &lt;1% as unchanged drug); feces (~17%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance: Plasma: Oral: 3 L/hour/kg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/61/15318/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wiker BN and K&auml;llen B, \"Are Hypnotic Benzodiazepine Receptor Agonists Teratogenic in Humans?\"",
"      <i>",
"       J Clin Psychopharmacol",
"      </i>",
"      , 2011, 31(3):356-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/61/15318/abstract-text/21508851/pubmed\" id=\"21508851\" target=\"_blank\">",
"        21508851",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10334 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-AB2AAAC1E4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_61_15318=[""].join("\n");
var outline_f14_61_15318=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235597\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235622\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235600\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235601\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235602\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235603\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235572\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235557\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235624\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7875059\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235575\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235573\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7913944\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235620\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235578\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235561\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235616\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235566\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235593\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235568\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235581\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235606\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14642029\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5648904\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235580\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235582\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235560\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235577\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10334\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10334|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?6/51/6965?source=related_link\">",
"      Zaleplon: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_61_15319="Chronic asthma in children younger than 12 years: Definition, epidemiology, and pathophysiology";
var content_f14_61_15319=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chronic asthma in children younger than 12 years: Definition, epidemiology, and pathophysiology",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/61/15319/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/61/15319/contributors\">",
"     Gregory Sawicki, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/61/15319/contributors\">",
"     Kenan Haver, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/61/15319/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/61/15319/contributors\">",
"     Robert A Wood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/61/15319/contributors\">",
"     Gregory Redding, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/61/15319/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/61/15319/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/61/15319/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H825021\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;This topic provides an overview of the epidemiology and pathophysiology of chronic childhood asthma. The evaluation and treatment of chronic childhood asthma is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26010?source=see_link\">",
"     \"Chronic asthma in children younger than 12 years: Evaluation and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39670?source=see_link\">",
"     \"Chronic asthma in children younger than 12 years: Quick-relief agents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37354?source=see_link\">",
"     \"Chronic asthma in children younger than 12 years: Controller medications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asthma is a chronic, inflammatory lung disease characterized by [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15319/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Symptoms of cough, wheezing, dyspnea, and chest tightness that occur in paroxysms and are usually related to specific triggering events",
"     </li>",
"     <li>",
"      Airway narrowing that is partially or completely reversible",
"     </li>",
"     <li>",
"      Increased airways responsiveness to a variety of stimuli",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A wide global variation exists in the prevalence of asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15319/abstract/2\">",
"     2",
"    </a>",
"    ]. Asthma is the most common chronic disease in childhood in first world countries. Recurrent asthma-like symptoms were reported in approximately 32 percent of preschool children in the United States and Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15319/abstract/3\">",
"     3",
"    </a>",
"    ]. Epidemiologic data estimate that nearly seven million children in the United States are diagnosed with asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15319/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data from the CDC-based National Center for Health Statistics showed an increase in asthma prevalence from 1980 to 1996 of greater than 50 percent (",
"    <a class=\"graphic graphic_figure graphicRef57994 \" href=\"UTD.htm?28/32/29198\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15319/abstract/5\">",
"     5",
"    </a>",
"    ]. The largest increase was seen in persons younger than 18 years [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15319/abstract/6-11\">",
"     6-11",
"    </a>",
"    ]. The CDC's 2006 National Health Interview Survey estimated a lifetime asthma prevalence of 13.5 percent (",
"    <a class=\"graphic graphic_table graphicRef72023 \" href=\"UTD.htm?30/61/31711\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15319/abstract/12\">",
"     12",
"    </a>",
"    ]. The estimated current asthma prevalence in general increased between 2001 and 2009 (",
"    <a class=\"graphic graphic_figure graphicRef57994 \" href=\"UTD.htm?28/32/29198\">",
"     figure 1",
"    </a>",
"    ), and was 9.6 percent among children &le;18 years in 2009 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15319/abstract/13\">",
"     13",
"    </a>",
"    ]. Asthma attack rates in the previous 12 months remained level between 1997 and 2009 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15319/abstract/13\">",
"     13",
"    </a>",
"    ]. The prevalence of asthma appears to have plateaued in other countries as well [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15319/abstract/14-18\">",
"     14-18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several hypotheses have been proposed to explain the increased frequency of asthma in all age groups, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Improved hygiene resulting in less exposure to infectious pathogens and an imbalance in the normal immune response [",
"      <a class=\"abstract\" href=\"UTD.htm?14/61/15319/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Increased indoor air pollution brought on by energy efficient building construction and recycled air, increased nitrogen dioxide and other irritant gases, cigarette smoke,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      increased allergens (especially cockroaches, cats, dust mites, molds).",
"     </li>",
"     <li>",
"      Increased incidence of early-onset respiratory viral infections [",
"      <a class=\"abstract\" href=\"UTD.htm?14/61/15319/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Enhanced host susceptibility (eg, more premature infants surviving with chronic lung disease).",
"     </li>",
"     <li>",
"      Congenitally small lungs due to maternal cigarette smoking [",
"      <a class=\"abstract\" href=\"UTD.htm?14/61/15319/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Increased awareness and recognition of asthma by patients and clinicians.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Epidemiologic risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of epidemiologic factors are associated with an increased risk of developing asthma. Individual risk factors are discussed in detail separately (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/12/20682?source=see_link\">",
"     \"Risk factors for asthma\"",
"    </a>",
"    ). National surveillance of asthma by the Centers for Disease Control has yielded the following trends in the United States population [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15319/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Gender",
"    </span>",
"    &nbsp;&mdash;&nbsp;Boys have a higher current prevalence of asthma than girls (11.0 versus 7.5 percent). This trend is reversed in adulthood, such that males have a lower prevalence than females (5.6 versus 8.9 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Race/ethnicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Differences in the current prevalence of childhood asthma are noted across various racial and ethnic groups, including African-Americans (12.7 percent), Puerto Ricans (25.7 percent), Mexican-Americans (6.6 percent), and whites (8.8 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Socioeconomic status",
"    </span>",
"    &nbsp;&mdash;&nbsp;Current asthma prevalence among children with family income below the federal poverty threshold is higher than among children with family income at or above the poverty threshold (12.2 versus 9.4 to 6.3 percent). These differences are most pronounced in urban settings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Locale",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urban dwellers are more likely than rural inhabitants to have asthma (7.1 versus 5.7 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15319/abstract/22\">",
"     22",
"    </a>",
"    ]. Childhood asthma is most prevalent in the Northeast (12.2 percent), compared with the Midwest (9.8 percent), South (8.6 percent), and West (7.6 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Social costs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vast economic and social toll which asthma cumulatively exacts is illustrated by the following data:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two-thirds of the children with this disease suffer noticeable disability.",
"     </li>",
"     <li>",
"      Ten million school days are missed each year due to the disease.",
"     </li>",
"     <li>",
"      Childhood asthma is a major cause of parental work absenteeism [",
"      <a class=\"abstract\" href=\"UTD.htm?14/61/15319/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An estimated $1.6",
"      <span class=\"nowrap\">",
"       billion/year",
"      </span>",
"      (excluding medication costs) is spent to care for children with asthma [",
"      <a class=\"abstract\" href=\"UTD.htm?14/61/15319/abstract/22,24-33\">",
"       22,24-33",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of childhood asthma is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/13/7383?source=see_link&amp;anchor=H2#H2\">",
"     \"Natural history of asthma\", section on 'Infants and children'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The symptoms of asthma are due to airflow obstruction resulting from the cumulative effects of smooth muscle constriction around airways, airway wall edema, intraluminal mucus accumulation, inflammatory cell infiltration of the submucosa, and basement membrane thickening (",
"    <a class=\"graphic graphic_figure graphicRef74177 \" href=\"UTD.htm?37/21/38226\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15319/abstract/34\">",
"     34",
"    </a>",
"    ]. Airway smooth muscle constriction can be severe, leading to life-threatening narrowing and closure of airways, even in the absence of mucous plugging. Both abnormal smooth muscle contractility and excess smooth muscle mass may contribute. Airway inflammation in asthma consists of mucosal, submucosal, and adventitial edema; cellular infiltration, particularly by eosinophils, activated helper T cells, mast cells, and sometimes neutrophils; increased airway secretions, including secreted mucus, desquamated lining cells, and intraluminal eosinophils; capillary engorgement; hyperplasia of smooth muscle; and deposition of excess collagen, particularly immediately beneath the basement membrane of the epithelium.",
"   </p>",
"   <p>",
"    Patients with fatal asthma exhibit pronounced pathologic changes in the segmental and subsegmental bronchi, with involvement of the small airways down to, but usually sparing, the respiratory bronchioles [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15319/abstract/35\">",
"     35",
"    </a>",
"    ]. These abnormalities include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Thickening of the basement membrane due to type IV collagen deposition",
"     </li>",
"     <li>",
"      Desquamation of the epithelial lining with loss of ciliated cells and partial regeneration by goblet and squamous cells",
"     </li>",
"     <li>",
"      Mucosal edema",
"     </li>",
"     <li>",
"      Airway smooth muscle thickening, with hyperplasia and hypertrophy of myocytes",
"     </li>",
"     <li>",
"      Luminal plugging with inflammatory cells (eosinophils, lymphocytes, mast cells, neutrophils), sloughed epithelial cells, tenacious mucus, and plasma proteins",
"     </li>",
"     <li>",
"      Submucosal infiltration by inflammatory cells, with deposition of submucosal connective tissue",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar but less extensive changes can be seen in the airways of asthmatics with less severe disease (",
"    <a class=\"graphic graphic_picture graphicRef65575 \" href=\"UTD.htm?20/41/21137\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15319/abstract/36-39\">",
"     36-39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many of these pathologic changes are reflected in the sputum. As examples, Charcot-Leyden crystals (eosinophil remnants), Curschmann's spirals (airway lumen casts of exudate), and Creola bodies (clumps of sloughed epithelial cells) can be found in the sputum of asthmatics [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15319/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physiologic consequences of asthma are a reduction in airway luminal diameter. The three defining components of asthmatic airflow obstruction are airway inflammation, reversible bronchoconstriction, and increased airways hyperresponsiveness to a variety of stimuli [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15319/abstract/1\">",
"     1",
"    </a>",
"    ]. Although the exact mechanisms are not fully understood, chronic airway inflammation, mediated by a variety of immune cells and mediators, results in the development of clinically recognizable asthma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/52/4937?source=see_link\">",
"     \"Pathogenesis of asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Airway inflammation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic airway inflammation is now recognized as an important component of disease in even the most mildly symptomatic patients. The recognition that chronic inflammatory changes begin at the onset of asthma symptoms has resulted in increasing use of antiinflammatory therapy. In fact, the mainstays of treatment for all forms of persistent asthma are the inhaled glucocorticoids (also called inhaled corticosteroids). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37354?source=see_link\">",
"     \"Chronic asthma in children younger than 12 years: Controller medications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Inflammatory cells, such as neutrophils, eosinophils, lymphocytes, and mast cells are abundant in asthmatic lungs [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15319/abstract/41\">",
"     41",
"    </a>",
"    ]. Multiple cytokines, including leukotrienes, have been found in bronchoalveolar lavage fluid of patients with asthma. IgE antibodies are also linked to progression of lung disease [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15319/abstract/41\">",
"     41",
"    </a>",
"    ]. In severe asthma, the exaggerated inflammatory response is associated with impaired glutathione homeostasis, a biomarker of oxidant stress [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15319/abstract/42\">",
"     42",
"    </a>",
"    ]. The decreased capacity to reduce reactive oxygen species leads to airway injury.",
"   </p>",
"   <p>",
"    Research into the chronic inflammation of asthma is ongoing. The results hold promise in identifying new therapeutic targets for the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15319/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Reversible airflow obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physiologic hallmark of asthma is reduced expiratory airflow. Spirometry is the preferred method for the diagnosis of obstruction. Airflow obstruction is defined as FEV1 of less than 80 percent predicted and a reduced",
"    <span class=\"nowrap\">",
"     FEV1/FVC",
"    </span>",
"    ratio of less than 0.8. Significant reversibility after administration of a short-acting bronchodilator is typically seen in asthma and is indicated by an increase in FEV1 of &ge;12 percent from baseline. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26010?source=see_link\">",
"     \"Chronic asthma in children younger than 12 years: Evaluation and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Airway hyperresponsiveness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Airway hyperresponsiveness is a hallmark of asthma and one measure of its severity. Airway responsiveness is defined as the degree to which airways narrow in response to a nonspecific stimulus, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"     methacholine",
"    </a>",
"    , cold air, or histamine [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15319/abstract/44\">",
"     44",
"    </a>",
"    ]. Asthmatic airways are hyperresponsive, such that less methacholine is needed to induce airflow obstruction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/4/1098?source=see_link\">",
"     \"Bronchoprovocation testing\"",
"    </a>",
"    .) Environmental triggers that increase airway responsiveness include viral upper respiratory infections [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15319/abstract/20\">",
"     20",
"    </a>",
"    ], allergens, and air pollutants.",
"   </p>",
"   <p>",
"    The degree of increased airway responsiveness correlates with asthma severity in children [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15319/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/9/44184?source=see_link\">",
"     \"Trigger control to enhance asthma management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nonspecific airways hyperresponsiveness (by criteria used for adults and older children) occurs in normal infants and lessens with age as the airways grow and increase in size [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15319/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. Induced bronchoconstriction in babies is reproducible, reversible, and inhibited by pretreatment with beta agonists [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15319/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?37/0/37892?source=see_link\">",
"       \"Patient information: Asthma symptoms and diagnosis in children (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?17/60/18374?source=see_link\">",
"       \"Patient information: Asthma treatment in children (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H824991\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Asthma is a chronic, inflammatory lung disease characterized by symptoms of cough, wheezing, dyspnea, and chest tightness that occur in paroxysms and are usually related to specific triggering events; airway narrowing that is partially or completely reversible; and increased airways responsiveness to a variety of stimuli. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A wide global variation exists in the prevalence of asthma. Asthma is the most common chronic disease in childhood in first world countries. A significant increase in the estimated prevalence of asthma was seen in developed countries in the 1980s and 1990s. Several hypotheses have been proposed to explain the increased frequency of asthma, including improved hygiene and increased indoor air pollution. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A number of epidemiologic factors are associated with an increased risk of developing asthma, including gender,",
"      <span class=\"nowrap\">",
"       race/ethnicity,",
"      </span>",
"      socioeconomic status, and locale. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiologic risk factors'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/12/20682?source=see_link\">",
"       \"Risk factors for asthma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The symptoms of asthma are due to airflow obstruction resulting from the cumulative effects of smooth muscle constriction around airways, airway wall edema, intraluminal mucus accumulation, inflammatory cell infiltration of the submucosa, and basement membrane thickening (",
"      <a class=\"graphic graphic_figure graphicRef74177 \" href=\"UTD.htm?37/21/38226\">",
"       figure 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Pathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The physiologic consequences of asthma are a reduction in airway luminal diameter. The three defining components of asthmatic airflow obstruction are airway inflammation, reversible bronchoconstriction, and increased airways hyperresponsiveness to a variety of stimuli. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Physiology'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     National Asthma Education and Prevention Program: Expert panel report III: Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Heart, Lung, and Blood Institute, 2007. (NIH publication no. 08-4051). www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm (Accessed on December 31, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15319/abstract/2\">",
"      Lai CK, Beasley R, Crane J, et al. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax 2009; 64:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15319/abstract/3\">",
"      Bisgaard H, Szefler S. Prevalence of asthma-like symptoms in young children. Pediatr Pulmonol 2007; 42:723.",
"     </a>",
"    </li>",
"    <li>",
"     National Health Interview Survey (NHIS 2006), National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention. Hyattsville, MD 2006. www.cdc.gov/nchs/fastats/asthma.htm (Accessed on December 16, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15319/abstract/5\">",
"      Mannino DM, Homa DM, Akinbami LJ, et al. Surveillance for asthma--United States, 1980-1999. MMWR Surveill Summ 2002; 51:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15319/abstract/6\">",
"      Evans R 3rd, Mullally DI, Wilson RW, et al. National trends in the morbidity and mortality of asthma in the US. Prevalence, hospitalization and death from asthma over two decades: 1965-1984. Chest 1987; 91:65S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15319/abstract/7\">",
"      Gergen PJ, Weiss KB. Changing patterns of asthma hospitalization among children: 1979 to 1987. JAMA 1990; 264:1688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15319/abstract/8\">",
"      Stein R, Canny GJ, Bohn DJ, et al. Severe acute asthma in a pediatric intensive care unit: six years' experience. Pediatrics 1989; 83:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15319/abstract/9\">",
"      Canny GJ, Reisman J, Healy R, et al. Acute asthma: observations regarding the management of a pediatric emergency room. Pediatrics 1989; 83:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15319/abstract/10\">",
"      Busse W, Banks-Schlegel SP, Larsen GL. Childhood- versus adult-onset asthma. Am J Respir Crit Care Med 1995; 151:1635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15319/abstract/11\">",
"      From the Centers for Disease Control. Asthma--United States, 1980-1990. JAMA 1992; 268:1995, 1999.",
"     </a>",
"    </li>",
"    <li>",
"     Data from National Health Interview Survey, 2006. National Center for Health Statistics. U.S. Department of Health and Human Services. Centers for Disease Control and Prevention. www.cdc.gov/asthma/NHIS/06/Data.htm (Accessed on December 16, 2008).",
"    </li>",
"    <li>",
"     Akinbami LJ, Moorman JE, Liu X. Asthma prevalence, health care use, and mortality: United States, 2005-2009. National Health Statistics Reports 2011; 32:1. www.cdc.gov/nchs/data/nhsr/nhsr032.pdf.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15319/abstract/14\">",
"      Anthracopoulos MB, Pandiora A, Fouzas S, et al. Sex-specific trends in prevalence of childhood asthma over 30 years in Patras, Greece. Acta Paediatr 2011; 100:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15319/abstract/15\">",
"      Zilmer M, Steen NP, Zachariassen G, et al. Prevalence of asthma and bronchial hyperreactivity in Danish schoolchildren: no change over 10 years. Acta Paediatr 2011; 100:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15319/abstract/16\">",
"      Wennergren G, Ekerljung L, Alm B, et al. Asthma in late adolescence--farm childhood is protective and the prevalence increase has levelled off. Pediatr Allergy Immunol 2010; 21:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15319/abstract/17\">",
"      Z&ouml;llner IK, Weiland SK, Piechotowski I, et al. No increase in the prevalence of asthma, allergies, and atopic sensitisation among children in Germany: 1992-2001. Thorax 2005; 60:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15319/abstract/18\">",
"      Osman M, Tagiyeva N, Wassall HJ, et al. Changing trends in sex specific prevalence rates for childhood asthma, eczema, and hay fever. Pediatr Pulmonol 2007; 42:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15319/abstract/19\">",
"      Warner JO. The hygiene hypothesis. Pediatr Allergy Immunol 2003; 14:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15319/abstract/20\">",
"      Gern JE. Viral respiratory infection and the link to asthma. Pediatr Infect Dis J 2008; 27:S97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15319/abstract/21\">",
"      Martinez FD, Morgan WJ, Wright AL, et al. Diminished lung function as a predisposing factor for wheezing respiratory illness in infants. N Engl J Med 1988; 319:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15319/abstract/22\">",
"      Gergen PJ, Mullally DI, Evans R 3rd. National survey of prevalence of asthma among children in the United States, 1976 to 1980. Pediatrics 1988; 81:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15319/abstract/23\">",
"      Weiss KB, Gergen PJ, Hodgson TA. An economic evaluation of asthma in the United States. N Engl J Med 1992; 326:862.",
"     </a>",
"    </li>",
"    <li>",
"     Coultas DB, Samet JM. Epidemiology and natural history of childhood asthma. In: Childhood asthma: Pathophysiology and treatment, Tinkelman DG, Naspitz CK (Eds), Marcel Dekker, New York 1993. p.71.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15319/abstract/25\">",
"      Clark D, Gollub R, Green WF, et al. Asthma in Jemez Pueblo schoolchildren. Am J Respir Crit Care Med 1995; 151:1625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15319/abstract/26\">",
"      Carter-Pokras OD, Gergen PJ. Reported asthma among Puerto Rican, Mexican-American, and Cuban children, 1982 through 1984. Am J Public Health 1993; 83:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15319/abstract/27\">",
"      Gottlieb DJ, Beiser AS, O'Connor GT. Poverty, race, and medication use are correlates of asthma hospitalization rates. A small area analysis in Boston. Chest 1995; 108:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15319/abstract/28\">",
"      Ferguson AC. Persisting airway obstruction in asymptomatic children with asthma with normal peak expiratory flow rates. J Allergy Clin Immunol 1988; 82:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15319/abstract/29\">",
"      Akhter J, Gaspar MM, Newcomb RW. Persistent peripheral airway obstruction in children with severe asthma. Ann Allergy 1989; 63:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15319/abstract/30\">",
"      Brown PJ, Greville HW, Finucane KE. Asthma and irreversible airflow obstruction. Thorax 1984; 39:131.",
"     </a>",
"    </li>",
"    <li>",
"     Godfrey SG. Childhood asthma. In: Asthma, 3rd ed, Clark TJH, Godfrey SG, Lee TH (Eds), Chapman &amp; Hall Medical, London 1992. p.551.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15319/abstract/32\">",
"      Cropp GJ. Special features of asthma in children. Chest 1985; 87:55S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15319/abstract/33\">",
"      Vance VJ, Taylor WF. The financial cost of chronic childhood asthma. Ann Allergy 1971; 29:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15319/abstract/34\">",
"      Fanta CH. Asthma. N Engl J Med 2009; 360:1002.",
"     </a>",
"    </li>",
"    <li>",
"     Hegele RG, Hogg JC. The pathology of asthma: An inflammatory disorder. In: Severe asthma: Pathogenesis and clinical management, Szefler S, Leung DYM (Eds), Marcel Dekker, New York 1996. p.61.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15319/abstract/36\">",
"      Laitinen LA, Heino M, Laitinen A, et al. Damage of the airway epithelium and bronchial reactivity in patients with asthma. Am Rev Respir Dis 1985; 131:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15319/abstract/37\">",
"      Sobonya RE. Quantitative structural alterations in long-standing allergic asthma. Am Rev Respir Dis 1984; 130:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15319/abstract/38\">",
"      Beasley R, Roche WR, Roberts JA, Holgate ST. Cellular events in the bronchi in mild asthma and after bronchial provocation. Am Rev Respir Dis 1989; 139:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15319/abstract/39\">",
"      Djukanovi�� R, Roche WR, Wilson JW, et al. Mucosal inflammation in asthma. Am Rev Respir Dis 1990; 142:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15319/abstract/40\">",
"      Fahy JV, Liu J, Wong H, Boushey HA. Cellular and biochemical analysis of induced sputum from asthmatic and from healthy subjects. Am Rev Respir Dis 1993; 147:1126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15319/abstract/41\">",
"      Busse WW, Lemanske RF Jr. Asthma. N Engl J Med 2001; 344:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15319/abstract/42\">",
"      Fitzpatrick AM, Teague WG, Holguin F, et al. Airway glutathione homeostasis is altered in children with severe asthma: evidence for oxidant stress. J Allergy Clin Immunol 2009; 123:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15319/abstract/43\">",
"      Barnes PJ. The cytokine network in asthma and chronic obstructive pulmonary disease. J Clin Invest 2008; 118:3546.",
"     </a>",
"    </li>",
"    <li>",
"     Larsen GL, Cherniack RM, Irvin CG. Pulmonary physiology of severe asthma in children and adults. In: Severe asthma: Pathogenesis and clinical management, Szefler SJ, Leung DY (Eds), Marcel Dekker, New York 1995. p.77.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15319/abstract/45\">",
"      Avital A, Noviski N, Bar-Yishay E, et al. Nonspecific bronchial reactivity in asthmatic children depends on severity but not on age. Am Rev Respir Dis 1991; 144:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15319/abstract/46\">",
"      Tepper RS. Airway reactivity in infants: a positive response to methacholine and metaproterenol. J Appl Physiol 1987; 62:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15319/abstract/47\">",
"      Montgomery GL, Tepper RS. Changes in airway reactivity with age in normal infants and young children. Am Rev Respir Dis 1990; 142:1372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15319/abstract/48\">",
"      Tepper RS. Airway reactivity in early childhood asthma: What are the questions. Am J Respir Crit Care Med 1995; 151:S19.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5741 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-C5FDE4D645-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_61_15319=[""].join("\n");
var outline_f14_61_15319=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H824991\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H825021\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Epidemiologic risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Gender",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Race/ethnicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Socioeconomic status",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Locale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Social costs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Airway inflammation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Reversible airflow obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Airway hyperresponsiveness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H824991\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/5741\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/5741|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/32/29198\" title=\"figure 1\">",
"      Prevalence rate of asthma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/21/38226\" title=\"figure 2\">",
"      Airway morphology in asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/5741|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/41/21137\" title=\"picture 1\">",
"      Endobronchial bx asthma High",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/5741|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/61/31711\" title=\"table 1\">",
"      Asthma prevalence age 2006",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/4/1098?source=related_link\">",
"      Bronchoprovocation testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37354?source=related_link\">",
"      Chronic asthma in children younger than 12 years: Controller medications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26010?source=related_link\">",
"      Chronic asthma in children younger than 12 years: Evaluation and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39670?source=related_link\">",
"      Chronic asthma in children younger than 12 years: Quick-relief agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/13/7383?source=related_link\">",
"      Natural history of asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/52/4937?source=related_link\">",
"      Pathogenesis of asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/0/37892?source=related_link\">",
"      Patient information: Asthma symptoms and diagnosis in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/60/18374?source=related_link\">",
"      Patient information: Asthma treatment in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/12/20682?source=related_link\">",
"      Risk factors for asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/9/44184?source=related_link\">",
"      Trigger control to enhance asthma management",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_61_15320="Medical disorders resulting in problem sleeplessness in children";
var content_f14_61_15320=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Medical disorders resulting in problem sleeplessness in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/61/15320/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/61/15320/contributors\">",
"     Stephen H Sheldon, DO, FAAP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/61/15320/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/61/15320/contributors\">",
"     Ronald D Chervin, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/61/15320/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/61/15320/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/61/15320/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 26, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H26318431\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Problems with sleep onset and maintenance are common complaints presenting to the child health care practitioner. A sleepless child affects the entire family, and symptoms of problem sleeplessness are often identified in several members of the same family. Sleeplessness may cause a child to have problems with daytime performance, behavior, or mood, regardless of the underlying cause of the sleeplessness.",
"   </p>",
"   <p>",
"    Problem sleeplessness in children (Pediatric insomnia) is a symptom of a heterogeneous group of disorders that include but are not limited to conditioned, behavioral,",
"    <span class=\"nowrap\">",
"     social/environmental,",
"    </span>",
"    circadian rhythm, and medical causes. The causes and clinical presentation of sleeplessness in children are quite different from those in adults, and the approach to diagnosis and management is correspondingly different.",
"   </p>",
"   <p>",
"    Little substantive literature exists exploring the association between medical conditions and sleeplessness in childhood. This topic review describes medical conditions that may be associated with sleeplessness in children. The general assessment of sleep disorders in children, and the diagnosis and management of behavioral sleep problems are discussed in separate topic reviews. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/50/5929?source=see_link\">",
"     \"Assessment of sleep disorders in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36806?source=see_link\">",
"     \"Behavioral sleep problems in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11018963\">",
"    <span class=\"h1\">",
"     OTITIS MEDIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Otitis media is common in children. Acute otitis media is typically characterized by ear pain, with or without associated fever, and rarely goes unrecognized. However, chronic middle ear disease may go unnoticed; serous or secretory otitis media associated with persistent middle ear effusions can present with disrupted nocturnal sleep, with few other symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11019965\">",
"    <span class=\"h2\">",
"     Acute otitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with acute suppurative otitis media typically present with fever, otalgia, changes in appetite, and vomiting, and may appear acutely ill. Prolonged or repeated arousals and wakings often occur, and may be associated with daytime sleepiness and a decrease in daytime activity levels. Physical examination reveals loss of normal tympanic membrane landmarks, erythema, or bulging of the tympanic membrane. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29642?source=see_link&amp;anchor=H21#H21\">",
"     \"Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Sleep disruption caused by acute otitis media should improve promptly with effective treatment of the infection. However, on occasion a child will have persistent sleep disruption after recovering from acute otitis media, either because of a persistent effusion, or because the wakings triggered a behavioral type of sleep problem. As an example, the parents&rsquo; response to the child&rsquo;s wakings may inadvertently reinforce the behavior. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/0/21514?source=see_link\">",
"     \"Acute otitis media in children: Treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36806?source=see_link&amp;anchor=H7#H7\">",
"     \"Behavioral sleep problems in children\", section on 'Transient forms'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11019972\">",
"    <span class=\"h2\">",
"     Chronic otitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast, chronic secretory or serous otitis media can be associated with few symptoms. Conductive hearing loss may be present, but this might be clinically unrecognized. The physical examination reveals a retracted tympanic membrane with limited mobility, and",
"    <span class=\"nowrap\">",
"     air/fluid",
"    </span>",
"    levels may be visualized behind the tympanic membrane. Sleep may be disrupted by ear discomfort. This discomfort might not be notable during daytime waking hours, but can become problematic during the nocturnal sleep period.",
"   </p>",
"   <p>",
"    Treatment options for chronic otitis media include watchful waiting, tympanotomy tube placement, a short course of antibiotic therapy, surgical placement of tympanostomy tubes, and adenotonsillectomy. Antihistamines and corticosteroids are not recommended. Indeed, antihistamines can have the paradoxical effect of causing or worsening the sleep disruption [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15320/abstract/1\">",
"     1",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11018971\">",
"    <span class=\"h1\">",
"     ALLERGIC RHINITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Difficulty initiating and maintaining sleep may occur in patients with seasonal allergic rhinitis or chronic allergic rhinitis. Allergic rhinitis affects up to 40 percent of children in the United States. Symptoms include sneezing, rhinorrhea, nasal congestion, pruritus, itching of the eyes and nose, insomnia, and daytime fatigue. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35370?source=see_link\">",
"     \"Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intranasal glucocorticoid sprays (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/63/37872?source=see_link\">",
"     fluticasone",
"    </a>",
"    propionate, fluticasone furoate,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/57/36752?source=see_link\">",
"     mometasone",
"    </a>",
"    furoate, or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/48/35584?source=see_link\">",
"     budesonide",
"    </a>",
"    ) have minimal systemic side effects and are the drugs of choice in the treatment of allergic rhinitis in children older than three years [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15320/abstract/2\">",
"     2",
"    </a>",
"    ]. Antihistamines have been shown to be effective in decreasing symptoms, but can also result in problem sleeplessness [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15320/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37834?source=see_link\">",
"     \"Pharmacotherapy of allergic rhinitis\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H11019011\">",
"     'Medication-induced sleep disturbance'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H350005059\">",
"    <span class=\"h1\">",
"     ATOPIC DERMATITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atopic dermatitis (eczema) is a common cause of sleeplessness in children [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15320/abstract/4\">",
"     4",
"    </a>",
"    ]. It affects between 5 and 20 percent of children, and causes sleep disruption in up to 60 percent of affected children [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15320/abstract/5\">",
"     5",
"    </a>",
"    ]. Sleep disruption is caused by itching or by the medications such as antihistamines or corticosteroids that are used to treat the dermatitis. Although the dermatitis is usually obvious, effective treatment may be challenging. &nbsp;",
"   </p>",
"   <p>",
"    The diagnosis and treatment of atopic dermatitis is discussed in separate topic reviews. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/40/42631?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of atopic dermatitis (eczema)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/37/10842?source=see_link\">",
"     \"Treatment of atopic dermatitis (eczema)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11018979\">",
"    <span class=\"h1\">",
"     NEUROLOGIC DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with neurologic impairment may exhibit problem sleeplessness, including difficulty initiating sleep, difficulty staying asleep, or both. Disordered",
"    <span class=\"nowrap\">",
"     sleep/wake",
"    </span>",
"    schedules and circadian rhythm disorders may also occur. Children with static encephalopathy, cortical and non-cortical blindness, and hearing impairment mediated by cranial nerve VIII are particularly susceptible to these sleep disturbances. Children with seizure disorders may also present with sleeplessness, sleepiness, or both. Sleep disorders are present among 20 to 45 percent of children with cerebral palsy, and include difficulty in initiating and maintaining sleep, sleep-wake transitions, and sleep related breathing disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15320/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Children with epilepsy or severe visual impairment are particularly at risk. In some cases, the sleep disturbances in these children are caused or exacerbated by the medications used to treat the underlying neurologic condition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11018987\">",
"    <span class=\"h2\">",
"     Clinical presentation and diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sleep problems in children with neurologic disorders may be due to a variety of underlying causes, including the neurologic condition itself, medications used to treat that condition, or non-neurologic factors. Therefore, assessment of the child's sleep problem must include a comprehensive evaluation, and the sleep disturbance should not be prematurely attributed to the neurologic condition itself. As examples, children with static encephalopathy and contractures may present with difficulty initiating and maintaining sleep that is usually attributable to discomfort and a need for repositioning than to the primary underlying neurologic abnormality. Children with spastic quadriplegia and other forms of static encephalopathy may have obstructive sleep apnea or gastroesophageal reflux that fragments sleep.",
"   </p>",
"   <p>",
"    Assessment of a sleep disorder in a child with a neurological condition resembles the approach taken in healthy children. Completion of a comprehensive sleep log is frequently helpful in evaluation of the sleep-wake cycle. The sleep log may help to identify a behavioral cause, instead of or in addition to a sleep disorder that arises from dysfunction of the neurologic mechanisms responsible for maintenance of sleep-wake cycles, sleep onset, or sleep maintenance. Medications used for management of the principal neurologic condition may also impair sleep. (See",
"    <a class=\"local\" href=\"#H11019011\">",
"     'Medication-induced sleep disturbance'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/50/5929?source=see_link&amp;anchor=H4#H4\">",
"     \"Assessment of sleep disorders in children\", section on 'Approach to the sleep history'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    If a pharmacologic or behavioral cause of the sleep disorder is not identified, nocturnal polysomnography may be useful. Polysomnography is the gold standard for diagnosis of obstructive sleep apnea and sleep-related movement disorders. For children with known or suspected seizure disorders, expanded polysomnographic electrode arrays can be used to assess for sleep-related seizure activity not apparent during wakefulness. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/38/44649?source=see_link\">",
"     \"Evaluation of suspected obstructive sleep apnea in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11018995\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of sleeplessness in a child with neurologic dysfunction is dependent upon the underlying cause. Factors that may influence sleep and the sleep-wake cycle, other than the neurologic disorder, should be considered first.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23656222\">",
"    <span class=\"h3\">",
"     Behavioral management",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a conditioned or behavioral problem is suspected, behavioral interventions, improvements in sleep hygiene, and cognitive behavioral therapy should be pursued. In comparison to healthy children, neurologically impaired children may require a more gradual introduction of behavioral interventions. The sleep-wake schedule should be addressed, especially in children with special sensory disorders such as blindness. Treatment of sleep schedule abnormalities can result in rapid improvement of sleep patterns and often can improve daytime function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36806?source=see_link&amp;anchor=H16#H16\">",
"     \"Behavioral sleep problems in children\", section on 'Behavioral interventions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If medications are thought to contribute to the sleeplessness, the timing and dose of medication might be modified. Alternatively, the clinician can consider substituting an alternative medication that is less likely to cause sleep disruption.",
"   </p>",
"   <p>",
"    Even if the underlying neurologic abnormality appears to cause the sleeplessness, the clinician and caretakers should still evaluate and optimize sleep hygiene [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15320/abstract/8\">",
"     8",
"    </a>",
"    ]. If improvement of sleeplessness occurs with mild medications, such as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/29/34256?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    , the child will most often show similar improvement without the use of drugs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23656215\">",
"    <span class=\"h3\">",
"     Pharmacotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypnotic or sedative medication is occasionally required for children with neurologic disorders who do not respond to sleep hygiene and other behavioral measures. If pharmacotherapy is used, nonpharmacologic strategies should also be used concurrently, including behavioral management and parental education. Treatment goals should be realistic, and should be discussed with the family before embarking on a trial of pharmacotherapy. &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    Selection of the appropriate medication depends on the specific sleep complaint, potential side effects, and interaction with concomitant medications [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15320/abstract/9\">",
"     9",
"    </a>",
"    ]. Drugs used for problems with sleep initiation should generally have quick onset and a short duration of action, whereas those used for problems with sleep maintenance require longer duration of action. However, the duration should not be so long that daytime sedation occurs. Ideally, there should be limited tolerance, few drug-drug interactions, and limited rebound sleeplessness.",
"   </p>",
"   <p>",
"    Classes of medication commonly used for sleeplessness in neurologically impaired children include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hormone analogs (eg, melatonin) &nbsp;",
"     </li>",
"     <li>",
"      Atypical antidepressants (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/46/744?source=see_link\">",
"       trazodone",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Benzodiazepines (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/34/32296?source=see_link\">",
"       diazepam",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/22/25959?source=see_link\">",
"       lorazepam",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Antihistamines (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/29/34256?source=see_link\">",
"       diphenhydramine",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/23/19830?source=see_link\">",
"       hydroxyzine",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Gamma-aminobutyric acid (GABA) alpha receptor agonists (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/38/26215?source=see_link\">",
"       zolpidem",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/11/15542?source=see_link\">",
"       eszopiclone",
"      </a>",
"      ) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is limited evidence on which to base decisions about pharmacotherapy for problem sleeplessness in children. Most of these drugs are not approved by the US Food and Drug Administration for this use in children; this is therefore an &ldquo;off label&rdquo; use. In our practice, we generally use one or more of the following strategies for patients who do not respond to sleep hygiene and other behavioral measures:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the patient appears to have frequent movements during sleep, or a family history of restless leg syndrome (RLS) or periodic limb movement disorder of sleep, we first attempt supplemental iron therapy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      measure serum iron and ferritin to assess for iron deficiency. This is because RLS is associated with iron deficiency in children [",
"      <a class=\"abstract\" href=\"UTD.htm?14/61/15320/abstract/10\">",
"       10",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/33/32282?source=see_link\">",
"       \"Restless legs syndrome and periodic limb movement disorder in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/2/38949?source=see_link\">",
"       \"Iron deficiency in infants and young children: Treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Melatonin is a second choice. Its use is based primarily on expert opinion, but clinical evidence is accumulating to support its safety and efficacy in some populations [",
"      <a class=\"abstract\" href=\"UTD.htm?14/61/15320/abstract/8,11\">",
"       8,11",
"      </a>",
"      ], as illustrated by the following examples:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A placebo-controlled trial in 51 children and adults with intellectual disabilities reported melatonin treatment resulted in clinically important improvements in initiation and maintenance of sleep, and increased total sleep time by a mean of 48 minutes [",
"      <a class=\"abstract\" href=\"UTD.htm?14/61/15320/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another randomized trial in 51 children with neurodevelopmental disabilities, prolonged-release melatonin treatment increased total night-time sleep by 30 minutes and reduced sleep latency by a similar amount [",
"      <a class=\"abstract\" href=\"UTD.htm?14/61/15320/abstract/13\">",
"       13",
"      </a>",
"      ]. All participants underwent an intervention to optimize sleep hygiene prior to beginning the pharmacologic intervention.",
"     </li>",
"     <li>",
"      In a randomized multicenter trial including 146 children with neurodevelopmental disorders, immediate-release melatonin shortened time to sleep onset by about 40 minutes, but it was also associated with slightly earlier awakening, resulting in a modest increase in total sleep time (22.4 minutes) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/61/15320/abstract/14\">",
"       14",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      We typically provide a prescription for 1 mg of melatonin, to be taken about 90 minutes prior to bedtime on an empty stomach. Liquid preparations and sublingual drops usually should be avoided due to the presence of alcohol (melatonin is not water soluble). We recommend nothing to eat 30 minutes prior to the dosing or 30 minutes following the dosing. The medication may be crushed and mixed with a small amount of applesauce or given with a small amount of apple or orange juice; this acidic medium can help with dissolution of the filler. Because melatonin is not regulated by the Food and Drug Administration (FDA), the content of preparations purchased in health food stores may vary. In our practice, we provide a prescription for melatonin to ensure that the preparation contains only melatonin, and is not part of a combination with other over-the-counter constituents. In addition, providing a prescription sometimes seems to help the patient and family engage seriously in the treatment process, including the associated behavioral management. Although early reports raised the possibility that melatonin might increase seizures in children with epilepsy, subsequent reports do not support this concern, and some suggest that melatonin may even reduce seizure activity [",
"      <a class=\"abstract\" href=\"UTD.htm?14/61/15320/abstract/15-17\">",
"       15-17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We have also found",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/23/35191?source=see_link\">",
"       gabapentin",
"      </a>",
"      helpful in small doses at bedtime. Depending upon the age of the child, we begin with 100 mg and titrate to a maximum of 300 mg. For younger children, particularly those with arousal disorders, we begin with 50 mg and titrate to a maximum of 150 mg.",
"     </li>",
"     <li>",
"      We generally avoid benzodiazepines and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/14/13545?source=see_link\">",
"       clonidine",
"      </a>",
"      . Benzodiazepines can be helpful, but only for a short time because tolerance develops; they are typically reserved for those children with co-morbidity, particularly those with neurological disorders. When benzodiazepines are required,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/22/25959?source=see_link\">",
"       lorazepam",
"      </a>",
"      is the first line choice, due to the onset of action and half life. We avoid",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/7/11383?source=see_link\">",
"       clonazepam",
"      </a>",
"      due to the long duration of action and, in our experience, the presence of significant hang-over effect. Clonidine is a very powerful REM suppressant and affects blood pressure even in normotensive individuals.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/38/26215?source=see_link\">",
"       Zolpidem",
"      </a>",
"      (Ambien&reg;) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/11/15542?source=see_link\">",
"       eszopiclone",
"      </a>",
"      (Lunesta&reg;) are utilized under specific circumstances, associated with behavioral and conditioning interventions. Although these agents have relatively low side-effect profiles in children, few data exist on tolerance and rebound once the hypnotic is withdrawn. In our practice, we reserve these hypnotics for use in children with underlying pathophysiological processes that cause difficulty initiating sleep (eg, children with middle fossa tumors resulting in hypothalamic dysfunction or severely neurologically challenged children who have difficulty maintaining sleep for more than a few hours).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/38/2662?source=see_link\">",
"       Chloral hydrate",
"      </a>",
"      has been used in the past for treatment of sleeplessness in children with neurologic or special sensory impairment. However, high doses are often required before sleep is improved, and many children have acute or chronic adverse effects, including sedation. Therefore, the usefulness of this drug is limited [",
"      <a class=\"abstract\" href=\"UTD.htm?14/61/15320/abstract/18\">",
"       18",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/42/24232?source=see_link\">",
"       \"Sedatives and hypnotics abuse and dependence: Pharmacology and epidemiology\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We do not recommend the use of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/29/34256?source=see_link\">",
"       diphenhydramine",
"      </a>",
"      or other antihistamines to induce sleep in children. A small controlled trial in infants 6 to 15 months of age showed that use of diphenhydramine resulted in no improvement in awakenings or parental satisfaction with the child&rsquo;s sleep as compared with placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?14/61/15320/abstract/19\">",
"       19",
"      </a>",
"      ]. Moreover, children may experience residual sedative effects or paradoxical hyperactivity during the day, and tolerance may develop with ongoing use.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Once medication is instituted, daytime function and sleep symptoms should be monitored to assess for efficacy and potential side effects. Periodic withdrawal of medication is also suggested. Once the symptoms of sleeplessness are controlled, it may be possible to discontinue the medication without exacerbation of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15320/abstract/20\">",
"     20",
"    </a>",
"    ]. Although medication is typically recommended only for short term use, prolonged use may be appropriate in some children with neurologic disability, if the benefits outweigh the risks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11019003\">",
"    <span class=\"h1\">",
"     ATTENTION DEFICIT HYPERACTIVITY DISORDER",
"    </span>",
"    &nbsp;&mdash;&nbsp;According to parental reports,",
"    <strong>",
"    </strong>",
"    hyperactive children have many more sleep problems than children without hyperactivity [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15320/abstract/21\">",
"     21",
"    </a>",
"    ]. The most common complaints concern night waking and restless sleep. In one report, parents of children with ADHD reported sleep onset problems occurring in 16.5 percent of patients and night waking in 39 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15320/abstract/22\">",
"     22",
"    </a>",
"    ]. Another report demonstrated that the frequency of insomnia significantly increases with stimulant therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15320/abstract/23\">",
"     23",
"    </a>",
"    ]; stimulant therapy was also associated with appetite disturbance, abdominal pain, headache, and dizziness. Behavioral issues (distractions and poor sleep hygiene) may also contribute to the problem. Some studies have suggested that mild obstructive sleep apnea is more common among children with attention",
"    <span class=\"nowrap\">",
"     deficit/hyperactivity",
"    </span>",
"    disorder than among their peers. This diagnosis should be considered because sleep apnea can also contribute to sleeplessness. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/19/14650?source=see_link&amp;anchor=H12#H12\">",
"     \"Pharmacology of drugs used to treat attention deficit hyperactivity disorder in children and adolescents\", section on 'Stimulant adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11019011\">",
"    <span class=\"h1\">",
"     MEDICATION-INDUCED SLEEP DISTURBANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A wide variety of medications can cause sleep disruption (",
"    <a class=\"graphic graphic_table graphicRef74374 \" href=\"UTD.htm?24/12/24783\">",
"     table 1",
"    </a>",
"    ), including some that are intended to treat the sleep problem. Although sedative-hypnotic drugs are often initiated as a treatment for sleep problems, they rarely solve the sleep problem in the long term; indeed, chronic use of these drugs frequently exacerbates the sleep problem. If improvement is noted when these medications are first tried, it is often due to its effects on sleep hygiene, and attention to appropriate sleep hygiene would have resulted in resolution of symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/46/17127?source=see_link\">",
"     \"The effects of medications on sleep quality and sleep architecture\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Medications that are commonly prescribed to treat sleep problems in children may paradoxically contribute to sleep disturbance. These include antihistamines and major sedatives (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/38/2662?source=see_link\">",
"     chloral hydrate",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/63/29689?source=see_link\">",
"     phenobarbital",
"    </a>",
"    , which may cause paradoxical hyperactivity). Benzodiazepines such as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/34/32296?source=see_link\">",
"     diazepam",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/22/25959?source=see_link\">",
"     lorazepam",
"    </a>",
"    are not generally useful for the management of sleep problems because of the development of tolerance, as well as abuse potential. However, the anxiolytic effects of benzodiazepines tend to persist, so some patients are able to use them for this purpose without undesirable sedation. Each of these classes of medications may result in residual daytime sleepiness and adversely affect daytime performance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/42/24232?source=see_link\">",
"     \"Sedatives and hypnotics abuse and dependence: Pharmacology and epidemiology\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H23656215\">",
"     'Pharmacotherapy'",
"    </a>",
"    above.) &nbsp;",
"   </p>",
"   <p>",
"    Seemingly innocuous medications prescribed for acute or chronic illness may also be responsible for sleeplessness. Orally administered bronchodilators (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/54/39782?source=see_link\">",
"     albuterol",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?23/49/24344?source=see_link\">",
"     theophylline",
"    </a>",
"    ) often cause sleep disruption through direct or indirect stimulation of the central nervous system. Inhaled bronchodilators are less likely to disrupt sleep because they tend to have a short duration of action. Antibiotics, especially liquid preparations, have been associated with difficulty initiating and maintaining sleep [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15320/abstract/20\">",
"     20",
"    </a>",
"    ]. The vehicle rather than the antibiotic itself may be responsible for the sleep disruption. Over-the-counter medications, especially combination drugs, may also be implicated. &nbsp;",
"   </p>",
"   <p>",
"    Several classes of drugs, including selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants, and monoamine oxidase inhibitors, may precipitate or exacerbate night-time movement disorders in adults (eg, bruxism or restless legs syndrome). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=see_link&amp;anchor=H19#H19\">",
"     \"Initial treatment of depression in adults\", section on 'Side effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Consumption of or withdrawal from caffeine, alcohol, and nicotine are associated with acute and sometimes chronic insomnia. The possibility of overt or covert use of these substances should be considered in children and adolescents with problem sleeplessness that is otherwise unexplained. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9561?source=see_link&amp;anchor=H3#H3\">",
"     \"Types of insomnia\", section on 'Acute insomnia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11019019\">",
"    <span class=\"h2\">",
"     Clinical presentation and diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medication history should be taken, including use of over-the-counter medications and herbal preparations. If the child is taking any medications, it is important to determine its dose and timing of administration. Although most medications do not result in marked or stereotypical patterns of sleep disruptions, nocturnal settling difficulties and nighttime waking problems may occur.",
"   </p>",
"   <p>",
"    Hypnotics, sedatives, and neuroleptics can cause significant changes in sleep architecture. Depending on the medication, total sleep time may be decreased, or the sleep-wake cycles may be shifted. For patients who are taking these medications, recording sleep patterns in a sleep diary for a period of two weeks is often helpful in documenting circadian sleep-wake rhythms. In addition, nocturnal polysomnography may be useful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11019027\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;If possible, the suspected offending medication should be discontinued. If this is not possible, modification of timing of administration or dose may be attempted. Switching to a similar medication or the same medication prepared differently may be successful (eg, changing from orally administered bronchodilators to inhaled preparations).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11019035\">",
"    <span class=\"h1\">",
"     CHRONIC ILLNESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many chronic conditions can contribute to persistent sleep problems. Pain or discomfort from the illness or from treatment regimens may be contributory. As an example, sleep abnormalities are common in children with juvenile idiopathic arthritis, and are multidimensional including nocturnal waking and parasomnias [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15320/abstract/24\">",
"     24",
"    </a>",
"    ]. Disorders such as migraine cephalgia, asthma, diabetes mellitus, gastroesophageal reflux, and seizures have all been associated with sleep disturbances [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15320/abstract/25-28\">",
"     25-28",
"    </a>",
"    ]. The problem of sleeplessness may be directly caused by the underlying disorder or may be an indirect consequence of therapy, medication, anxieties, or pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11019043\">",
"    <span class=\"h2\">",
"     Clinical presentation and diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is often difficult to isolate factors related to the illness that precipitate the sleep problems. In some cases, the cause of the sleep disruption is obvious, as in a child whose sleep is disrupted because of itching associated with chronic eczematous dermatitis. In many other cases it is unclear whether the sleep disruption is caused by the primary illness, associated symptoms, side effects of medication or therapy, or the family's or child's response to the illness. Therefore, each of these factors must be considered during a thorough evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11019051\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment is based on management of the underlying chronic disorder, control of associated symptoms, and appropriate attention to sleep hygiene. If parental or patient anxiety about the chronic illness is suspected, appropriate supportive interventions should be recommended. The potential roles of medication or cognitive behavioral therapy in the setting of sleeplessness due to chronic medical disorders remain largely unstudied.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11019117\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of medical problems may contribute to sleep disturbance in children and are often compounded by behavioral problems, inadequate sleep hygiene, or adverse effects of medications. Such problems include: &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Otitis media &mdash; On occasion a child will have persistent sleep disruption after recovering from acute otitis media, either because of a persistent effusion or because of the wakings triggered a behavioral type of sleep problem. Chronic secretory or serous otitis media may disrupt sleep in children even if minimal clinical symptoms appear during the day. (See",
"      <a class=\"local\" href=\"#H11018963\">",
"       'Otitis media'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Allergic rhinitis &mdash; Seasonal allergic rhinitis or chronic allergic rhinitis often impair initiation or maintenance of sleep. Responsible symptoms can include sneezing, rhinorrhea, nasal congestion, pruritus, and itching of the eyes and nose, which can all contribute to insomnia and daytime fatigue. (See",
"      <a class=\"local\" href=\"#H11018971\">",
"       'Allergic rhinitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Eczema &mdash; Up to 60 percent of children with atopic dermatitis (eczema) have disrupted sleep, which is caused by itching or by medications such as antihistamines or corticosteroids used to treat the dermatitis. (See",
"      <a class=\"local\" href=\"#H350005059\">",
"       'Atopic dermatitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Neurologic disorders &mdash; Children with neurologic disorders are at increased risk for problem sleeplessness. This may be caused by the neurologic condition itself (causing disturbance of sleep-wake cycles), discomfort due to comorbidities, medications used to treat that condition, or conditioned or behavioral factors. (See",
"      <a class=\"local\" href=\"#H11018979\">",
"       'Neurologic disorders'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Behavioral management and efforts to improve sleep hygiene should be included in any management plan. (See",
"      <a class=\"local\" href=\"#H23656222\">",
"       'Behavioral management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pharmacotherapy is occasionally required for children with neurologic disorders who do not respond to sleep hygiene and other behavioral measures. If pharmacotherapy is used, nonpharmacologic strategies should also be used concurrently, including behavioral management and parental education. (See",
"      <a class=\"local\" href=\"#H23656215\">",
"       'Pharmacotherapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Attention",
"      <span class=\"nowrap\">",
"       deficit/hyperactivity",
"      </span>",
"      disorder &mdash; Children with attention",
"      <span class=\"nowrap\">",
"       deficit/hyperactivity",
"      </span>",
"      disorder often have associated problems with sleep initiation or maintenance. These symptoms are sometimes but not always associated with stimulant therapy. Behavioral issues also may contribute to the problem. (See",
"      <a class=\"local\" href=\"#H11019003\">",
"       'Attention deficit hyperactivity disorder'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Medication-induced sleep disturbance &mdash; A wide variety of medications can cause sleep disruption, including some that are intended to treat the sleep problem (",
"      <a class=\"graphic graphic_table graphicRef74374 \" href=\"UTD.htm?24/12/24783\">",
"       table 1",
"      </a>",
"      ). Although sedative-hypnotic drugs are often prescribed in practice as a treatment for sleeplessness, for most children these agents are not optimal long term strategies. Indeed, chronic use of these drugs can exacerbate the sleep problem. (See",
"      <a class=\"local\" href=\"#H11019011\">",
"       'Medication-induced sleep disturbance'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H23656215\">",
"       'Pharmacotherapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15320/abstract/1\">",
"      Jones MC, Jones CE 2nd. Use of cetirizine in a 23-month-old male causes insomnia. South Med J 2010; 103:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15320/abstract/2\">",
"      Scadding GK. Corticosteroids in the treatment of pediatric allergic rhinitis. J Allergy Clin Immunol 2001; 108:S59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15320/abstract/3\">",
"      Kaiser HB, Banov CH, Berkowitz RR, et al. Comparative efficacy and safety of once-daily versus twice-daily loratadine-pseudoephedrine combinations versus placebo in seasonal allergic rhinitis. Am J Ther 1998; 5:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15320/abstract/4\">",
"      Smaldone A, Honig JC, Byrne MW. Sleepless in America: inadequate sleep and relationships to health and well-being of our nation's children. Pediatrics 2007; 119 Suppl 1:S29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15320/abstract/5\">",
"      Lewis-Jones S. Quality of life and childhood atopic dermatitis: the misery of living with childhood eczema. Int J Clin Pract 2006; 60:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15320/abstract/6\">",
"      Newman CJ, O'Regan M, Hensey O. Sleep disorders in children with cerebral palsy. Dev Med Child Neurol 2006; 48:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15320/abstract/7\">",
"      Simard-Tremblay E, Constantin E, Gruber R, et al. Sleep in children with cerebral palsy: a review. J Child Neurol 2011; 26:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15320/abstract/8\">",
"      Mindell JA, Emslie G, Blumer J, et al. Pharmacologic management of insomnia in children and adolescents: consensus statement. Pediatrics 2006; 117:e1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15320/abstract/9\">",
"      Owens JA, Babcock D, Blumer J, et al. The use of pharmacotherapy in the treatment of pediatric insomnia in primary care: rational approaches. A consensus meeting summary. J Clin Sleep Med 2005; 1:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15320/abstract/10\">",
"      Simakajornboon N, Gozal D, Vlasic V, et al. Periodic limb movements in sleep and iron status in children. Sleep 2003; 26:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15320/abstract/11\">",
"      Khan S, Heussler H, McGuire T, et al. Melatonin for non-respiratory sleep disorders in visually impaired children. Cochrane Database Syst Rev 2011; :CD008473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15320/abstract/12\">",
"      Braam W, Didden R, Smits M, Curfs L. Melatonin treatment in individuals with intellectual disability and chronic insomnia: a randomized placebo-controlled study. J Intellect Disabil Res 2008; 52:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15320/abstract/13\">",
"      Wasdell MB, Jan JE, Bomben MM, et al. A randomized, placebo-controlled trial of controlled release melatonin treatment of delayed sleep phase syndrome and impaired sleep maintenance in children with neurodevelopmental disabilities. J Pineal Res 2008; 44:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15320/abstract/14\">",
"      Gringras P, Gamble C, Jones AP, et al. Melatonin for sleep problems in children with neurodevelopmental disorders: randomised double masked placebo controlled trial. BMJ 2012; 345:e6664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15320/abstract/15\">",
"      Uberos J, Augustin-Morales MC, Molina Carballo A, et al. Normalization of the sleep-wake pattern and melatonin and 6-sulphatoxy-melatonin levels after a therapeutic trial with melatonin in children with severe epilepsy. J Pineal Res 2011; 50:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15320/abstract/16\">",
"      Elkhayat HA, Hassanein SM, Tomoum HY, et al. Melatonin and sleep-related problems in children with intractable epilepsy. Pediatr Neurol 2010; 42:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15320/abstract/17\">",
"      Andersen IM, Kaczmarska J, McGrew SG, Malow BA. Melatonin for insomnia in children with autism spectrum disorders. J Child Neurol 2008; 23:482.",
"     </a>",
"    </li>",
"    <li>",
"     Sheldon SH. Disorders of Initiating and Maintaining Sleep. In: Pediatric Sleep Medicine: Principles and Practice, Sheldon SH, Ferber R, Kryger MH (Eds), Elsevier/Saunders, Philadelphia 2005. p.138.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15320/abstract/19\">",
"      Merenstein D, Diener-West M, Halbower AC, et al. The trial of infant response to diphenhydramine: the TIRED study--a randomized, controlled, patient-oriented trial. Arch Pediatr Adolesc Med 2006; 160:707.",
"     </a>",
"    </li>",
"    <li>",
"     Ferber R. The sleepless child. In: Sleep and its Disorders in Children, Guilliminault C (Ed), Raven Press, New York 1987. p.141.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15320/abstract/21\">",
"      Kaplan BJ, McNicol J, Conte RA, Moghadam HK. Sleep disturbance in preschool-aged hyperactive and nonhyperactive children. Pediatrics 1987; 80:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15320/abstract/22\">",
"      Salzarulo P, Chevalier A. Sleep problems in children and their relationship with early disturbances of the waking-sleeping rhythms. Sleep 1983; 6:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15320/abstract/23\">",
"      Ahmann PA, Waltonen SJ, Olson KA, et al. Placebo-controlled evaluation of Ritalin side effects. Pediatrics 1993; 91:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15320/abstract/24\">",
"      Bloom BJ, Owens JA, McGuinn M, et al. Sleep and its relationship to pain, dysfunction, and disease activity in juvenile rheumatoid arthritis. J Rheumatol 2002; 29:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15320/abstract/25\">",
"      Ulualp S, Brodsky L. Nasal pain disrupting sleep as a presenting symptom of extraesophageal acid reflux in children. Int J Pediatr Otorhinolaryngol 2005; 69:1555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15320/abstract/26\">",
"      Luc ME, Gupta A, Birnberg JM, et al. Characterization of symptoms of sleep disorders in children with headache. Pediatr Neurol 2006; 34:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15320/abstract/27\">",
"      LaPlant MM, Adams BS, Haftel HM, Chervin RD. Insomnia and quality of life in children referred for limb pain. J Rheumatol 2007; 34:2486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15320/abstract/28\">",
"      Palermo TM, Fonareva I, Janosy NR. Sleep quality and efficiency in adolescents with chronic pain: relationship with activity limitations and health-related quality of life. Behav Sleep Med 2008; 6:234.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15602 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-3011E4F32C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_61_15320=[""].join("\n");
var outline_f14_61_15320=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11019117\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26318431\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11018963\">",
"      OTITIS MEDIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11019965\">",
"      Acute otitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11019972\">",
"      Chronic otitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11018971\">",
"      ALLERGIC RHINITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H350005059\">",
"      ATOPIC DERMATITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11018979\">",
"      NEUROLOGIC DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11018987\">",
"      Clinical presentation and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11018995\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23656222\">",
"      - Behavioral management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23656215\">",
"      - Pharmacotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11019003\">",
"      ATTENTION DEFICIT HYPERACTIVITY DISORDER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11019011\">",
"      MEDICATION-INDUCED SLEEP DISTURBANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11019019\">",
"      Clinical presentation and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11019027\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11019035\">",
"      CHRONIC ILLNESS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11019043\">",
"      Clinical presentation and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11019051\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11019117\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/15602\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/15602|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/12/24783\" title=\"table 1\">",
"      Drugs that affect sleep in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29642?source=related_link\">",
"      Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/0/21514?source=related_link\">",
"      Acute otitis media in children: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/50/5929?source=related_link\">",
"      Assessment of sleep disorders in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36806?source=related_link\">",
"      Behavioral sleep problems in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35370?source=related_link\">",
"      Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/40/42631?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of atopic dermatitis (eczema)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/38/44649?source=related_link\">",
"      Evaluation of suspected obstructive sleep apnea in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=related_link\">",
"      Initial treatment of depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/2/38949?source=related_link\">",
"      Iron deficiency in infants and young children: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/19/14650?source=related_link\">",
"      Pharmacology of drugs used to treat attention deficit hyperactivity disorder in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37834?source=related_link\">",
"      Pharmacotherapy of allergic rhinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/33/32282?source=related_link\">",
"      Restless legs syndrome and periodic limb movement disorder in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/42/24232?source=related_link\">",
"      Sedatives and hypnotics abuse and dependence: Pharmacology and epidemiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/46/17127?source=related_link\">",
"      The effects of medications on sleep quality and sleep architecture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/37/10842?source=related_link\">",
"      Treatment of atopic dermatitis (eczema)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9561?source=related_link\">",
"      Types of insomnia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_61_15321="Solid organ transplantation in HIV-infected individuals";
var content_f14_61_15321=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Solid organ transplantation in HIV-infected individuals",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/61/15321/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/61/15321/contributors\">",
"     Pablo Tebas, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/61/15321/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/61/15321/contributors\">",
"     Daniel C Brennan, MD, FACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/61/15321/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/61/15321/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/61/15321/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/61/15321/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Liver, kidney, and heart transplantation are the current treatments of choice for advanced organ failure. However, human immunodeficiency virus (HIV) infection was traditionally considered an",
"    <strong>",
"     absolute",
"    </strong>",
"    contraindication for transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15321/abstract/1\">",
"     1",
"    </a>",
"    ]. One of the principal concerns was that immunosuppression would accelerate",
"    <span class=\"nowrap\">",
"     HIV/acquired",
"    </span>",
"    immune deficiency syndrome (AIDS), resulting in increased mortality and a \"waste\" of organs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/55/26490?source=see_link\">",
"     \"Evaluation of the potential renal transplant recipient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since highly active antiretroviral therapy (HAART) became widely available in 1996, the prognosis of HIV infection has dramatically improved. There have been significant decreases in morbidity and mortality, and for many individuals with well-controlled viral replication,",
"    <span class=\"nowrap\">",
"     HIV/AIDS",
"    </span>",
"    is now a chronic manageable disease [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15321/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=see_link\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Previously, HIV-infected individuals with very advanced disease frequently died from opportunistic infections (OIs). Among such individuals, the presence of chronic diseases, such as renal insufficiency, coronary artery disease, diabetes mellitus, or liver failure (associated with hepatitis B or C virus co-infection), were not significant causes of mortality. The situation is currently quite different, as these co-morbidities as well as others are real medical problems for many individuals with well-controlled HIV replication [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15321/abstract/3-6\">",
"     3-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Such improvements in the long-term prognosis of those with HIV infection have prompted many transplant programs to reevaluate their policies regarding the exclusion of patients with HIV infection. A review of the issues surrounding solid organ transplantation in HIV-infected patients is presented here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OUTCOMES BEFORE HAART",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the availability of a reliable diagnostic test for HIV infection, some individuals unknowingly infected with HIV underwent solid organ transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15321/abstract/7-11\">",
"     7-11",
"    </a>",
"    ]. Others acquired HIV infection by receiving an organ from a HIV-positive individual [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15321/abstract/12-18\">",
"     12-18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite some positive experiences [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15321/abstract/19,20\">",
"     19,20",
"    </a>",
"    ], many of these patients had poorer outcomes than those observed with HIV-negative individuals. However, data from that era is hard to evaluate for the following reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients had been infected for variable periods of time, including infection that occurred before, during, or after transplantation.",
"     </li>",
"     <li>",
"      There were remarkable differences in the types of immunosuppression administered [",
"      <a class=\"abstract\" href=\"UTD.htm?14/61/15321/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Some were HIV \"slow-progressors.\" However, there were only a handful of such individuals [",
"      <a class=\"abstract\" href=\"UTD.htm?14/61/15321/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Overview of medical literature",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following is a brief introduction to the literature surrounding outcomes of transplant patients infected with HIV prior to the widespread use of HAART [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15321/abstract/8,15,16,23-28\">",
"     8,15,16,23-28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a case series of 11 liver recipients infected with HIV, the seven-year survival rate was 36 percent compared to approximately 70 percent in HIV-negative patients [",
"      <a class=\"abstract\" href=\"UTD.htm?14/61/15321/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An analysis from 1998 showed poor outcomes in HIV-positive hemophiliac patients who underwent liver transplantation in the United States, Canada, and Europe between 1982 to 1996 [",
"      <a class=\"abstract\" href=\"UTD.htm?14/61/15321/abstract/25\">",
"       25",
"      </a>",
"      ]. Six of 26 recipients were HIV-positive, and their three-year survival was 23 versus 83 percent for those who were seronegative.",
"     </li>",
"     <li>",
"      A case series of 22 HIV-infected renal transplant recipients in France revealed a five and seven year death rate of 50 and 70 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?14/61/15321/abstract/15\">",
"       15",
"      </a>",
"      ]. By comparison, the five-year survival rate was 84 percent in HIV-infected subjects on dialysis. Similar results were observed in Italy [",
"      <a class=\"abstract\" href=\"UTD.htm?14/61/15321/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The University of Pittsburgh had the largest clinical experience in the transplantation of HIV-positive patients in these early years [",
"      <a class=\"abstract\" href=\"UTD.htm?14/61/15321/abstract/8,27,28\">",
"       8,27,28",
"      </a>",
"      ]. In a review of 25 HIV-positive individuals transplanted between 1981 to 1988, the prognosis of adults was poor. The survival after a mean period of 2.75 years (0.7 to 6.6 years) was 46 percent (7 of 15) for liver recipients, 40 percent (2 of 5) for heart recipients and 80 percent (4 of 5) for kidney recipients. AIDS was the leading cause of death in adults [",
"      <a class=\"abstract\" href=\"UTD.htm?14/61/15321/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All of these experiences, when combined with the feeling that",
"    <span class=\"nowrap\">",
"     HIV/AIDS",
"    </span>",
"    was a progressively fatal disease, prompted most transplant programs to reject prospective transplant recipients with concomitant HIV infection. During the following years, HIV transplants became a rarity. HIV-positive patients who had been accidentally transplanted died and the development of adequate screening tests prevented the transplantation of HIV-positive organs.",
"   </p>",
"   <p>",
"    In the early 1990s, when clinicians and patients were desperate for treatments for AIDS, one center even tried xenotransplantation. An individual co-infected with HBV and HIV received the liver of a baboon (report from 1993) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15321/abstract/29\">",
"     29",
"    </a>",
"    ]. Given its lack of success and paucity of data, it is unlikely that xenotransplantation would be permitted in the current era.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SOLID ORGAN TRANSPLANTATION IN THE HAART ERA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The improvement in outcomes with HAART has called into question the previous policy of systematically denying transplantation to HIV-infected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15321/abstract/1,30\">",
"     1,30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Liver transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several transplantation units in the United States and Europe have begun to transplant livers to HIV-infected individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15321/abstract/31-38\">",
"     31-38",
"    </a>",
"    ]. Investigators from the University of Pittsburgh presented results of a prospective trial evaluating the experience of five different centers in the United States and Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15321/abstract/32\">",
"     32",
"    </a>",
"    ]. Twenty-three HIV-infected individuals received transplants between 1997 and 2001. The median survival was 15 months, with all 16 survivors tolerating HAART after liver transplantation. In contrast, seven patients who died did not tolerate HAART. In addition, all who died were co-infected with HCV. Preliminary results revealed that possible prognostic factors for a good outcome were the absence of concurrent hepatitis C infection, ability to tolerate HAART, and CD4 cell count. Additional predictors seemed to be age (those who died were younger and more likely to be hemophiliacs) and viral load. The one-year survival rate was approximately 61 percent.",
"   </p>",
"   <p>",
"    A retrospective cohort study reported the outcomes of liver transplantation among 138 HIV positive patients compared with 30,529 HIV negative recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15321/abstract/39\">",
"     39",
"    </a>",
"    ]. HIV infection was associated with a lower two-year survival (70 versus 81 percent). However, this was attributed to coinfection with hepatitis B or C virus, since no HIV positive patients without hepatitis B or C virus died at an average follow-up of 1.2 years per person.",
"   </p>",
"   <p>",
"    A prospective cohort study revealed slightly worse outcomes of liver transplantation among patients coinfected with HIV and hepatitis C (HCV) compared with patients infected only with HCV [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15321/abstract/40\">",
"     40",
"    </a>",
"    ]. At three years, patient and graft survival were significantly lower in coinfected individuals compared with HCV-infected individuals who were not coinfected with HIV (60 versus 79 and 53 versus 74 percent, respectively). HIV infection was the only factor significantly associated with reduced patient and graft survival. Among co-infected patients, older donor age, combined kidney-liver transplant, an HCV-positive donor, and low body mass index predicted graft loss. The cumulative incidence of severe HCV disease was not different between groups.",
"   </p>",
"   <p>",
"    The overall worse outcomes may have been related in part to an increased rate of rejection among coinfected patients. At three years, the incidence of treated acute rejection was 1.6-fold higher in HCV-HIV coinfected individuals compared with HCV-infected individuals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Renal transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies have demonstrated excellent outcomes in HIV-infected patients who underwent renal transplant in the HAART era [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15321/abstract/31,36,37,41-46\">",
"     31,36,37,41-46",
"    </a>",
"    ]. The largest study to date is a prospective nonrandomized trial that examined outcomes of kidney transplantation in 150 carefully selected recipients who had CD4+ T-cell counts of at least 200 per mm3 and undetectable HIV RNA levels [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15321/abstract/46\">",
"     46",
"    </a>",
"    ]. Patients were followed for a median of 1.7 years; 53 patients completed at least 3 years of follow-up. Patient survival at 1 and 3 years was 95 and 88 percent respectively; allograft survival was 90 and 74 percent. These survival rates fall somewhere in between those for recipients older than 65 years of age and those for all kidney-transplant recipients as reported by the US Scientific Registry of Transplant Recipients (SRTR).",
"   </p>",
"   <p>",
"    One of the findings in current studies of renal transplantation in HIV-infected individuals has been the high frequency of rejection. In the study cited above, 1- and 3-year rejection rates were 31 and 41 percent compared to a 1-year rejection rate of 12 percent as reported by SRTR for all kidney transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15321/abstract/46\">",
"     46",
"    </a>",
"    ]. The relatively high rate of rejection may have been related to nontherapeutic exposure to immunosuppressive agents in this study. Because some HAART regimens inhibit the cytochrome P-450 system, almost one third of the enrolled patients received calcineurin inhibitors less frequently than is generally prescribed (i.e., every other or every third day). Although the one-month trough",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    levels were consistent with those reported for non-HIV-infected kidney transplant recipients, it is possible that total exposure to calcineurin inhibitors was subtherapeutic. In a multivariate proportional hazards model, the use of a kidney from a deceased donor and cyclosporine use were independently associated with an increased risk of graft rejection with hazard ratios of 2.3 and 2.1, respectively. The use of antiretrovirals such as integrase inhibitors that do not inhibit the P-450 system, may simplify the use of immunosuppressants in this setting and decrease the frequency of rejection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/34/7720?source=see_link\">",
"     \"Clinical trials of HIV antiretroviral therapy: Integrase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several studies have reported significant decreases in CD4 counts in HIV-infected recipients that is related to the use of thymoglobulin [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15321/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. In the study cited above, the median change in the CD4+ count from baseline to 1 year was greater in patients who received induction therapy with thymoglobulin compared to those who did not (-239 versus -135 cells per mm(3)) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15321/abstract/46\">",
"     46",
"    </a>",
"    ]. However, these changes were transient; the median change in CD4+ count from baseline to 3 years was not significantly different between these groups (-57 and -52 cells per mm(3), respectively). Furthermore, there was no evidence of accelerated HIV disease progression or HIV-associated complications among transplant recipients in this study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Heart transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heart transplant programs have been more reluctant to transplant HIV-positive individuals. A fatal outcome of a heart recipient in Italy was reported in 1998 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15321/abstract/48\">",
"     48",
"    </a>",
"    ]. There has been no nationwide study conducted for HIV-infected subjects receiving heart transplants.",
"   </p>",
"   <p>",
"    The Cleveland Clinic performed at least two heart transplants into HIV-infected recipients in 2001. A report about one of these patients 24 months after transplantation revealed that the transplant had been successful despite a number of episodes of rejection (treated with pulses of corticosteroids); the HIV viral load was still &lt;50",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    (undetectable) despite fluctuations in the CD4 count [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15321/abstract/49\">",
"     49",
"    </a>",
"    ]. No opportunistic infections or recrudescence of the patient's previous Kaposi's sarcoma occurred despite the administration of immunosuppressing drugs. An accompanying editorial supports transplantation in well-controlled HIV-infected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15321/abstract/50\">",
"     50",
"    </a>",
"    ]. The patient subsequently died during 2004.",
"   </p>",
"   <p>",
"    Columbia Presbyterian Medical Center published the largest experience regarding heart transplantation in HIV infected individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15321/abstract/51\">",
"     51",
"    </a>",
"    ]. Among 1679 transplants, seven patients with HIV infection were identified, five who were diagnosed with&nbsp;HIV&nbsp;before transplantation and two who seroconverted after transplantation. The CD4 count was 554",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    and the viral load was undetectable in all patients at transplantation. Viral load remained low in the presence of immunosuppression and all patients were alive at 57 months. These encouraging results suggest that heart transplantation is a reasonable option in well selected HIV-infected individuals",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple retrospective and some prospective studies show that clinical outcomes differ between HIV-infected transplant recipients and HIV-seronegative patients enlisted in the UNOS database. Although the one-year survival rates appear comparable between the two groups, the three-year survival rates are significantly less compared with living donor or standard criteria donor recipients. Furthermore, the frequency of rejection, particularly among renal transplants is markedly higher [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15321/abstract/46,47\">",
"     46,47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CHEMOKINE RECEPTORS, TRANSPLANTATION AND HIV INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;CCR5, a chemokine receptor of the CC family, is the main co-receptor of the macrophage tropic strains of HIV-1. This was discovered because CCR5 is also a receptor for the chemokines RANTES, MIP-1alpha, and MIP-1beta, which are the major HIV-suppressive factors produced by CD8 T cells [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15321/abstract/52\">",
"     52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/34/5674?source=see_link\">",
"     \"Immunology of HIV-1 infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/27/10682?source=see_link\">",
"     \"Transplantation immunobiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Approximately 1 percent of Caucasians are homozygous carriers of an allele of the gene for the CC chemokine receptor 5 (CCR5) with a 32 bp deletion (CCR5del32), which leads to an inactive receptor. Approximately 15 percent of the population is heterozygous for this gene [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15321/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Individuals with a 32 base pair deletion in the CCR5 molecule are highly resistant to infection with HIV-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15321/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. Other studies have also demonstrated that individuals that are homozygous for this gene have a lower risk of asthma, rheumatoid arthritis, and multiple sclerosis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15321/abstract/55-57\">",
"     55-57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The relationship between renal allograft survival and CCR5 genotype was evaluated in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15321/abstract/58\">",
"     58",
"    </a>",
"    ]. Among 1227 renal transplant recipients, 21 were homozygous for CCR5del32, 248 were heterozygous for CCR5del32, and 958 were homozygous for wild-type CCR5. Long-term follow-up was available for 576 patients. The individuals that were homozygous for CCR5del32 showed a clear survival advantage over the other two groups (hazard ratio 0.367 [95% CI 0.157-0.859]). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/53/14170?source=see_link\">",
"     \"Risk factors for graft failure in kidney transplantation\"",
"    </a>",
"    .) The exact mechanism of this improved survival is unknown. It could represent some functional immunologic impairment that prevents rejection or it could be related to the development of antibodies against this molecule, thereby blocking the effects of RANTES, MIP-1alpha, and MIP-1beta in the individuals that have received the allograft.",
"   </p>",
"   <p>",
"    CCR5 is therefore a very attractive target for the development of new antiretrovirals that block entry of the HIV virus, with several compounds being developed.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/45/20182?source=see_link\">",
"     Maraviroc",
"    </a>",
"    was approved and cenicriviroc (TBR-652) is in phase II studies [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15321/abstract/59,60\">",
"     59,60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, compounds that block CCR5 might be used in the future as adjuvants in transplantation. Such drugs could potentially be used in any patient who is not homozygous for CCR5del32, not only for HIV-infected individuals. An NIH-funded study (#NCT00948753) is evaluating",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/45/20182?source=see_link\">",
"     maraviroc",
"    </a>",
"    for the prevention of graft-versus-host disease in patients undergoing non-myeloablative allogeneic stem-cell transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15321/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PHARMACOLOGICAL ASPECTS AFTER TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;How to administer a complex immunosuppressive regimen in combination with potent antiretroviral therapy poses a major challenge following solid organ transplantation in HIV-infected individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15321/abstract/11\">",
"     11",
"    </a>",
"    ]. Contemporary treatment of HIV infection involves the combination of at least three",
"    <strong>",
"     fully active",
"    </strong>",
"    drugs from the currently available classes of antiretroviral medications: nucleoside analog reverse transcriptase inhibitors (NRTI), non-nucleoside analog reverse transcriptase inhibitors (NNRTIs), HIV-protease inhibitors (PIs), entry inhibitors and integrase inhibitors. The standard for an initial antiretroviral regimen includes the combination of two nucleoside analogs and a pharmacologically boosted protease inhibitor or two nucleoside analogs and a NNRTI. Multiple other combinations are possible and are commonly used because of toxicity of the initial regimen or the need for rescue therapy if the patient develops virologic failure",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    drug resistance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=see_link\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Protease inhibitors, especially",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    , have profound inhibitory effects on P450 cytochrome isoenzymes; one such isoenzyme CYP3A4 is critical for the metabolism of calcineurin inhibitors (CI) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15321/abstract/62-64\">",
"     62-64",
"    </a>",
"    ]. Thus, PIs can significantly reduce metabolism and increase the blood levels of CI [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15321/abstract/65\">",
"     65",
"    </a>",
"    ]. (See",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?37/62/38880?source=see_link\">",
"     \"Cyclosporine: Patient drug information\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/29/12759?source=see_link\">",
"     \"Dose modification of antiretroviral agents in adults with renal or hepatic dysfunction\"",
"    </a>",
"    .) Cobicistat is another potent CYP3A4 antagonist that is in the late phase of development.",
"   </p>",
"   <p>",
"    On average, only 25 percent of the standard dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    (CSA) is required if administered concomitantly with PIs. Similarly, the dose of",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"      tacrolimus",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"      sirolimus",
"     </a>",
"    </span>",
"    must be decreased significantly (eg, to 1 to 2 mg tacrolimus weekly) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15321/abstract/36\">",
"     36",
"    </a>",
"    ]; other investigators have suggested a tacrolimus dose of 1 mg every other day to once weekly if HAART contains a PI, but a dose of 0.1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in case of a NNRTI-based regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15321/abstract/34\">",
"     34",
"    </a>",
"    ]. According to one case report, the interaction between",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/62/19433?source=see_link\">",
"     nelfinavir",
"    </a>",
"    and tacrolimus required dose-reduction by a factor of 70 compared with standard dosing [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15321/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one study, the pharmacokinetics and dosing modifications in 35 patients (20 kidney, 13 liver and two kidney-liver HIV-infected subjects with end-stage kidney or liver disease) on both immunosuppressants and NNRTIs, PIs, and combined NNRTIs + PIs was reported [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15321/abstract/66\">",
"     66",
"    </a>",
"    ]. HIV-infected transplant recipients using PIs with immunosuppressants had marked increases in CsA,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    through levels compared to those on NNRTIs alone or to patients not on ARVs, necessitating either a reduction in dose or an increase in dosing interval. Subjects on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    (EFV) and CsA required much higher doses of CsA than those using any other ARV.",
"   </p>",
"   <p>",
"    Non-nucleoside analog reverse transcriptase inhibitors can also affect the metabolism of P450 enzymes in an even more complex way than PIs:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/10/27816?source=see_link\">",
"       Delavirdine",
"      </a>",
"      is an inhibitor of P450 enzymes and the prediction would be that it would increase the levels of drugs like CSA or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"       Efavirenz",
"      </a>",
"      exhibits mixed",
"      <span class=\"nowrap\">",
"       inhibitory/inducing",
"      </span>",
"      effects on some of the isoenzymes of the P450 system.",
"     </li>",
"     <li>",
"      The use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"       nevirapine",
"      </a>",
"      in HIV patients undergoing liver transplantation is generally avoided due to concerns of potential drug related hepatotoxicity. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/29/12759?source=see_link\">",
"       \"Dose modification of antiretroviral agents in adults with renal or hepatic dysfunction\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In general, the experience with this class of drugs in transplant recipients is still limited, and close monitoring of serum levels of immunosuppressants is mandatory.",
"   </p>",
"   <p>",
"    Other drugs used commonly after transplantation, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil (MMF), may interact with nucleoside analogs like",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    (ZDV) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    (d4T), making them less effective [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15321/abstract/67\">",
"     67",
"    </a>",
"    ]. Unfortunately, the effects are exactly the opposite with other members of this class of drugs: mycophenolate is associated with increases in the effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    (ddI) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15321/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"     Atazanavir",
"    </a>",
"    , a protease inhibitor, should be used with caution because the use of proton pump inhibitors (that are frequently used in transplantation) interferes with its absorption.",
"   </p>",
"   <p>",
"    There is less information about the use of other antiretroviral drugs, like entry inhibitors (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/45/20182?source=see_link\">",
"     maraviroc",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15321/abstract/59,60\">",
"     59,60",
"    </a>",
"    ] and integrase inhibitors (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     Raltegravir",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15321/abstract/69,70\">",
"     69,70",
"    </a>",
"    ] in patients with solid organ transplants. Maraviroc interacts with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    , a protease inhibitor that is used frequently to boost the levels of other protease inhibitors, and should be used cautiously in patients receiving protease inhibitors. Raltegravir has low potential for interactions with other antiretrovirals or other drugs used for the management of transplants, and have been used successfully in a few cases.",
"   </p>",
"   <p>",
"    Fortunately, the potential for immunosuppressants to cause subtherapeutic levels of antiretrovirals appears to be minimal. Antiretroviral medications are generally used in normal doses (and adjusted to the improved kidney or liver function that occurs after the transplantation). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/29/12759?source=see_link\">",
"     \"Dose modification of antiretroviral agents in adults with renal or hepatic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thymoglobulin, an agent frequently used to manage acute rejection, may be associated with marked CD4 positive depletion [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15321/abstract/47\">",
"     47",
"    </a>",
"    ]. This was shown an observational study of 20 consecutive kidney recipients, 11 of which received thymoglobulin. The mean CD4 cell count decreased from 475 to 9",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    after thymoglobulin administration, which successfully reversed rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15321/abstract/47\">",
"     47",
"    </a>",
"    ]. Despite this, only one case of candida esophagitis was seen. There was no increased risk of opportunistic infections or progression to AIDS or death. Thymoglobulin should be used with caution in this population, and prophylaxis against opportunistic infections reinitiated if the patient was not receiving it previously.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because interactions between anti-rejection and antiretroviral drugs can be significant, close drug level monitoring is extremely important. Consultation and interaction between the transplant and the infectious diseases teams is particularly important when considering changes in any pharmaceutical regimen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     VIRAL HEPATITIS RECURRENCE AFTER TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrence of HCV after liver transplantation remains a significant challenge for all transplantation programs independent of HIV status [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15321/abstract/67\">",
"     67",
"    </a>",
"    ]. It particularly affects patients with HIV infection because co-infection is very common. Recurrence contributes to increased posttransplant morbidity and mortality.",
"   </p>",
"   <p>",
"    The effects of co-infection with HCV and HIV in liver transplantation outcomes need to be carefully evaluated, as this may be a poor prognostic factor in this population. Combination therapy with pegylated interferon and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    is the treatment of choice, but the frequency of attaining a durable response is lower than in non-transplanted patients and survival is decreased [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15321/abstract/71\">",
"     71",
"    </a>",
"    ]. Combination therapy with direct antiviral agents like",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    is being evaluated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/5/16474?source=see_link\">",
"     \"Liver transplantation for hepatitis C virus infection\"",
"    </a>",
"    .) The need to use adjunctive therapy with growth factors and antidepressants adds another layer of complexity in this situation.",
"   </p>",
"   <p>",
"    Hepatitis B virus infection also merits special attention, as most of the patients co-infected with HIV have evidence of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    (3TC) resistance. This is because 3TC has been administered for years as part of the combination regimens to treat HIV infection.",
"   </p>",
"   <p>",
"    Fortunately, new drugs are becoming available for the treatment of HBV infections:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"       Adefovir",
"      </a>",
"      , originally developed for the treatment of HIV infection, was too nephrotoxic at the doses required to produce an antiretroviral effect. However, it is a potent, well-tolerated drug when used at much lower doses (10 mg daily) for the treatment of HBV infection.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"       Tenofovir",
"      </a>",
"      shows very promising activity against HBV, even in the presence of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      resistance [",
"      <a class=\"abstract\" href=\"UTD.htm?14/61/15321/abstract/72,73\">",
"       72,73",
"      </a>",
"      ] and is probably superior to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"       adefovir",
"      </a>",
"      in monoinfected individuals [",
"      <a class=\"abstract\" href=\"UTD.htm?14/61/15321/abstract/74\">",
"       74",
"      </a>",
"      ]. Tenofovir was approved by the FDA for this indication in 2008.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"       Entecavir",
"      </a>",
"      , a very potent nucleoside with activity at least comparable to the previously discussed agent, has been approved for the treatment of HBV infection. There have been reports that suggests that entecavir may have some anti-HIV activity and contribute to the development of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      resistance if not given as part of fully suppressive regimens [",
"      <a class=\"abstract\" href=\"UTD.htm?14/61/15321/abstract/75\">",
"       75",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"       Telbivudine",
"      </a>",
"      , an l-nucleoside with potent and specific anti-HBV activity, was approved for the treatment of HBV and has a favorable safety profile. In a large phase 3 trial, it was found to be as effective, if not slightly better than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      in the management of patients with HBV infection [",
"      <a class=\"abstract\" href=\"UTD.htm?14/61/15321/abstract/76\">",
"       76",
"      </a>",
"      ]. Compared to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"       adefovir",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      and lamivudine, telbivudine does not appear to have any antiHIV activity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     Tenofovir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    should be used as part of a fully suppressive HAART regimen, even if they are exclusively used for their HBV activity to prevent the development of HIV resistance with a partially suppressive regimen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23030?source=see_link\">",
"     \"Investigational treatments of chronic hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Administration of anti-HBV Immunoglobulins is an important posttransplant therapeutic tool to prevent reinfection of the transplanted organ.",
"   </p>",
"   <p>",
"    All HIV-infected patients, especially those with evidence of chronic liver disease, should be vaccinated against hepatitis A. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/55/7033?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of hepatitis B in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     OTHER COMPLICATIONS AFTER SOLID ORGAN TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is difficult to separate the complications of particular opportunistic infections associated with HIV progression from the complications associated with the immunosuppression required for the transplantation. Although experience is still too limited to know what the relative contribution of each of these two factors will be, it is more likely that infections will be related to the posttransplant immunosuppressive state rather than to the HIV infection, since all transplant programs require full control of viral replication and a CD4 cell count above 200",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    prior to transplantation for kidney transplants or greater than 100",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    for liver transplants.",
"   </p>",
"   <p>",
"    Prophylaxis against opportunistic infections is certainly indicated for this patient population after transplantation. As previously mentioned, however, it is important to stress that AIDS-defining illnesses are no longer the leading cause of life-compromising diseases in HIV-infected patients in contrast to the pre-HAART era [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15321/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     CURRENT TRANSPLANT ELIGIBILITY CRITERIA IN THE UNITED STATES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The policy of systematically denying transplantation to HIV-infected patients was called into question after it became clear that HIV-seropositive patients were responding very favorably to antiretroviral therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15321/abstract/1,30\">",
"     1,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Apart from organized initiatives, some transplant centers are considering solid organ transplantation for HIV-positive individuals on a case-by-case basis. It is likely a matter of time before transplantation will become widely available to all HIV-infected individuals with well-controlled viral replication and organ failure.",
"   </p>",
"   <p>",
"    Obviously, regular indications and contraindications for transplantation also apply in HIV-infected patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/55/26490?source=see_link\">",
"     \"Evaluation of the potential renal transplant recipient\"",
"    </a>",
"    .) In addition, the current organized transplant studies require a CD4 cell count above 200",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    for all organs except liver (100",
"    <span class=\"nowrap\">",
"     cells/microL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15321/abstract/73\">",
"     73",
"    </a>",
"    ]. The reason for this different criterion is the concern for splenic sequestration in patients with advanced liver disease and portal hypertension. Another entry criterion of the CCTAT program is the requirement that patients be on a stable potent antiretroviral regimen for at least three months and have an undetectable HIV RNA level.",
"   </p>",
"   <p>",
"    Exceptions to the requirement of an undetectable viral load are granted for patients who cannot tolerate HAART because of drug-associated toxicity, provided that the patient will likely achieve an undetectable HIV viral load (based upon genotypic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    phenotypic testing) if the medications are started in the posttransplant period. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32424?source=see_link\">",
"     \"Drug resistance testing in the clinical management of HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Exclusion criteria include a history of opportunistic infections (but the patient will be eligible if immune reconstitution has occurred) or major neoplasms that might require the use of systemic chemotherapy. Patients with end-stage liver disease are not eligible for kidney transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV infection should no longer be an absolute contraindication for transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15321/abstract/77,78\">",
"     77,78",
"    </a>",
"    ]. In selected cases, patients should be eligible for solid organ transplantation if they have well-controlled HIV-infection. The decision to transplant a specific patient should be individualized.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15321/abstract/1\">",
"      Spital A. Should all human immunodeficiency virus-infected patients with end-stage renal disease be excluded from transplantation? The views of U.S. transplant centers. Transplantation 1998; 65:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15321/abstract/2\">",
"      Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15321/abstract/3\">",
"      Kaplan JE, Hanson DL, Jones JL, et al. Viral load as an independent risk factor for opportunistic infections in HIV-infected adults and adolescents. AIDS 2001; 15:1831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15321/abstract/4\">",
"      Kaplan JE, Hanson D, Dworkin MS, et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis 2000; 30 Suppl 1:S5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15321/abstract/5\">",
"      Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 32:492.",
"     </a>",
"    </li>",
"    <li>",
"     Wolfe, M, Selik, R, Swerdlow, DL. Deaths from Non-AIDS-Related Diseases Have Increased as a Proportion of Deaths of HIV-Infected Persons since the Advent of HAART. 9th Conference on Retroviruses and Opportunistic Infections; February 24-28, 2002; Seattle, Washington. Abstract 14.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15321/abstract/7\">",
"      Tzakis AG, Cooper MH, Dummer JS, et al. Transplantation in HIV+ patients. Transplantation 1990; 49:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15321/abstract/8\">",
"      Dummer JS, Erb S, Breinig MK, et al. Infection with human immunodeficiency virus in the Pittsburgh transplant population. A study of 583 donors and 1043 recipients, 1981-1986. Transplantation 1989; 47:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15321/abstract/9\">",
"      Rubin RH, Jenkins RL, Shaw BW Jr, et al. The acquired immunodeficiency syndrome and transplantation. Transplantation 1987; 44:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15321/abstract/10\">",
"      Shaffer D, Pearl RH, Jenkins RL, et al. HTLV-III/LAV infection in kidney and liver transplantation. Transplant Proc 1987; 19:2176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15321/abstract/11\">",
"      Izzedine H, Launay-Vacher V, Baumelou A, Deray G. Antiretroviral and immunosuppressive drug-drug interactions: an update. Kidney Int 2004; 66:532.",
"     </a>",
"    </li>",
"    <li>",
"     Ho, M. Infection and organ transplantation. In: Anesthesia and organ transplantation, Gelman, S (Ed), Saunders, Philadelphia 1987, p. 49.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15321/abstract/13\">",
"      al-Sulaiman M, al-Khader AA, al-Hasani MK, Dhar JM. Impact of HIV infection on dialysis and renal transplantation. Transplant Proc 1989; 21:1970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15321/abstract/14\">",
"      Keay S, Behrens MT, Klassen D, et al. Impact asymptomatic HIV-1 infection on renal allograft recipients. Transplant Proc 1993; 25:1478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15321/abstract/15\">",
"      Lang P, Niaudet P. Update and outcome of renal transplant patients with human immunodeficiency virus. The Groupe Cooperatif de Transplantation de I'lle de France. Transplant Proc 1991; 23:1352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15321/abstract/16\">",
"      Glassock RJ, Cohen AH, Danovitch G, Parsa KP. Human immunodeficiency virus (HIV) infection and the kidney. Ann Intern Med 1990; 112:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15321/abstract/17\">",
"      Prompt CA, Reis MM, Grillo FM, et al. Transmission of AIDS virus at renal transplantation. Lancet 1985; 2:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15321/abstract/18\">",
"      Schvarcz R, Rudbeck G, S&ouml;derdahl G, St&aring;hle L. Interaction between nelfinavir and tacrolimus after orthoptic liver transplantation in a patient coinfected with HIV and hepatitis C virus (HCV). Transplantation 2000; 69:2194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15321/abstract/19\">",
"      Jacobson SK, Calne RY, Wreghitt TG. Outcome of HIV infection in transplant patient on cyclosporin. Lancet 1991; 337:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15321/abstract/20\">",
"      Vanhems P, Bresson-Hadni S, Vuitton DA, et al. Long-term survival without immunosuppression in HIV-positive liver-graft recipient. Lancet 1991; 337:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15321/abstract/21\">",
"      Schwarz A, Offermann G, Keller F, et al. The effect of cyclosporine on the progression of human immunodeficiency virus type 1 infection transmitted by transplantation--data on four cases and review of the literature. Transplantation 1993; 55:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15321/abstract/22\">",
"      Purgus R, Tamalet C, Poignard P, et al. Long-term nonprogressive human immunodeficiency virus-1 infection in a kidney allograft recipient. Transplantation 1998; 66:1384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15321/abstract/23\">",
"      Bouscarat F, Samuel D, Simon F, et al. An observational study of 11 French liver transplant recipients infected with human immunodeficiency virus type 1. Clin Infect Dis 1994; 19:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15321/abstract/24\">",
"      Erice A, Rhame FS, Heussner RC, et al. Human immunodeficiency virus infection in patients with solid-organ transplants: report of five cases and review. Rev Infect Dis 1991; 13:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15321/abstract/25\">",
"      Gordon FH, Mistry PK, Sabin CA, Lee CA. Outcome of orthotopic liver transplantation in patients with haemophilia. Gut 1998; 42:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15321/abstract/26\">",
"      Poli F, Scalamogna M, Pizzi C, et al. HIV infection in cadaveric renal allograft recipients in the North Italy Transplant Program. Transplantation 1989; 47:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15321/abstract/27\">",
"      Bontempo FA, Lewis JH, Gorenc TJ, et al. Liver transplantation in hemophilia A. Blood 1987; 69:1721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15321/abstract/28\">",
"      Ragni MV, Bontempo FA, Lewis JH. Organ transplantation in HIV-positive patients with hemophilia. N Engl J Med 1990; 322:1886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15321/abstract/29\">",
"      Starzl TE, Fung J, Tzakis A, et al. Baboon-to-human liver transplantation. Lancet 1993; 341:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15321/abstract/30\">",
"      Halpern SD, Ubel PA, Caplan AL. Solid-organ transplantation in HIV-infected patients. N Engl J Med 2002; 347:284.",
"     </a>",
"    </li>",
"    <li>",
"     Roland, MS, Carlson, L. Liver and kidney transplantation in HIV-infected patients: A preliminary multi-site experience. 9th Conference on Retroviruses and Opportunistic Infections; February 24-28, 2002; Seattle, Washington. Abstract 655.",
"    </li>",
"    <li>",
"     Ragni M NG, Heaton N. Antiretroviral therapy and mortality among HIV-positive liver transplant recipients. 9th Conference on Retroviruses and Opportunistic Infections; February 24-28 2002; Seattle, Washington. Abstract 125.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15321/abstract/33\">",
"      Prachalias AA, Pozniak A, Taylor C, et al. Liver transplantation in adults coinfected with HIV. Transplantation 2001; 72:1684.",
"     </a>",
"    </li>",
"    <li>",
"     Fung, J. Clinical experiences with HIV and transplantation. Oral Presentation. American Society of Transplantation (AST) Winter Symposium; January 19, 2002; Olympic Valley, California.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15321/abstract/35\">",
"      Wreghitt T. Liver Transplantation in Adults Coinfected With HIV. Transplantation 2001; 72: 1684. Transplantation 2001; 72:1594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15321/abstract/36\">",
"      Stock P, Roland M, Carlson L, et al. Solid organ transplantation in HIV-positive patients. Transplant Proc 2001; 33:3646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15321/abstract/37\">",
"      Stock PG, Roland ME, Carlson L, et al. Kidney and liver transplantation in human immunodeficiency virus-infected patients: a pilot safety and efficacy study. Transplantation 2003; 76:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15321/abstract/38\">",
"      Neff GW, Bonham A, Tzakis AG, et al. Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease. Liver Transpl 2003; 9:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15321/abstract/39\">",
"      Mindikoglu AL, Regev A, Magder LS. Impact of human immunodeficiency virus on survival after liver transplantation: analysis of United Network for Organ Sharing database. Transplantation 2008; 85:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15321/abstract/40\">",
"      Terrault NA, Roland ME, Schiano T, et al. Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection. Liver Transpl 2012; 18:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15321/abstract/41\">",
"      Abbott KC, Swanson SJ, Agodoa LY, Kimmel PL. Human immunodeficiency virus infection and kidney transplantation in the era of highly active antiretroviral therapy and modern immunosuppression. J Am Soc Nephrol 2004; 15:1633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15321/abstract/42\">",
"      El Sayegh S, Keller MJ, Huprikar S, Murphy B. Solid organ transplantation in HIV-infected recipients. Pediatr Transplant 2004; 8:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15321/abstract/43\">",
"      Kumar MS, Sierka DR, Damask AM, et al. Safety and success of kidney transplantation and concomitant immunosuppression in HIV-positive patients. Kidney Int 2005; 67:1622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15321/abstract/44\">",
"      Qiu J, Terasaki PI, Waki K, et al. HIV-positive renal recipients can achieve survival rates similar to those of HIV-negative patients. Transplantation 2006; 81:1658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15321/abstract/45\">",
"      Roland ME, Barin B, Carlson L, et al. HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes. Am J Transplant 2008; 8:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15321/abstract/46\">",
"      Stock PG, Barin B, Murphy B, et al. Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med 2010; 363:2004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15321/abstract/47\">",
"      Carter JT, Melcher ML, Carlson LL, et al. Thymoglobulin-associated Cd4+ T-cell depletion and infection risk in HIV-infected renal transplant recipients. Am J Transplant 2006; 6:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15321/abstract/48\">",
"      Calabrese F, Angelini A, Cecchetto A, et al. HIV infection in the first heart transplantation in Italy: fatal outcome. Case report. APMIS 1998; 106:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15321/abstract/49\">",
"      Calabrese LH, Albrecht M, Young J, et al. Successful cardiac transplantation in an HIV-1-infected patient with advanced disease. N Engl J Med 2003; 348:2323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15321/abstract/50\">",
"      Roland ME, Havlir DV. Responding to organ failure in HIV-infected patients. N Engl J Med 2003; 348:2279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15321/abstract/51\">",
"      Uriel N, Jorde UP, Cotarlan V, et al. Heart transplantation in human immunodeficiency virus-positive patients. J Heart Lung Transplant 2009; 28:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15321/abstract/52\">",
"      Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000; 12:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15321/abstract/53\">",
"      Doranz BJ, Rucker J, Yi Y, et al. A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 1996; 85:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15321/abstract/54\">",
"      Dean M, Carrington M, Winkler C, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996; 273:1856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15321/abstract/55\">",
"      Hall IP, Wheatley A, Christie G, et al. Association of CCR5 delta32 with reduced risk of asthma. Lancet 1999; 354:1264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15321/abstract/56\">",
"      Zapico I, Coto E, Rodr&iacute;guez A, et al. CCR5 (chemokine receptor-5) DNA-polymorphism influences the severity of rheumatoid arthritis. Genes Immun 2000; 1:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15321/abstract/57\">",
"      Sellebjerg F, Madsen HO, Jensen CV, et al. CCR5 delta32, matrix metalloproteinase-9 and disease activity in multiple sclerosis. J Neuroimmunol 2000; 102:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15321/abstract/58\">",
"      Fischereder M, Luckow B, Hocher B, et al. CC chemokine receptor 5 and renal-transplant survival. Lancet 2001; 357:1758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15321/abstract/59\">",
"      Gulick RM, Lalezari J, Goodrich J, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008; 359:1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15321/abstract/60\">",
"      F&auml;tkenheuer G, Nelson M, Lazzarin A, et al. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med 2008; 359:1442.",
"     </a>",
"    </li>",
"    <li>",
"     file://clinicaltrials.gov/ct2/show/NCT00948753?term=maraviroc&amp;rank=9 (Accessed on December 15, 2010).",
"    </li>",
"    <li>",
"     Roland, MS, Carlson, L, et al. Solid organ transplantation in HIV disease. 8th Conference on Retroviruses and Opportunistic Infections; February 2001; Chicago. Abstract 579.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15321/abstract/63\">",
"      Gow PJ, Pillay D, Mutimer D. Solid organ transplantation in patients with HIV infection. Transplantation 2001; 72:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15321/abstract/64\">",
"      Frassetto L, Baluom M, Jacobsen W, et al. Cyclosporine pharmacokinetics and dosing modifications in human immunodeficiency virus-infected liver and kidney transplant recipients. Transplantation 2005; 80:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15321/abstract/65\">",
"      Sheikh AM, Wolf DC, Lebovics E, et al. Concomitant human immunodeficiency virus protease inhibitor therapy markedly reduces tacrolimus metabolism and increases blood levels. Transplantation 1999; 68:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15321/abstract/66\">",
"      Frassetto LA, Browne M, Cheng A, et al. Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients. Am J Transplant 2007; 7:2816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15321/abstract/67\">",
"      Fishman JA, Rubin RH. Solid organ transplantation in HIV-infected individuals: obstacles and opportunities. Transplant Proc 2001; 33:1310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15321/abstract/68\">",
"      Heredia A, Margolis D, Oldach D, et al. Abacavir in combination with the inosine monophosphate dehydrogenase (IMPDH)-inhibitor mycophenolic acid is active against multidrug-resistant HIV-1. J Acquir Immune Defic Syndr 1999; 22:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15321/abstract/69\">",
"      Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008; 359:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15321/abstract/70\">",
"      Cooper DA, Steigbigel RT, Gatell JM, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 2008; 359:355.",
"     </a>",
"    </li>",
"    <li>",
"     Forman, LM. Orthotopic liver transplantation for hepatitis C: analysis of allograft survival using the UNOS database. 2001. Abstract 84.",
"    </li>",
"    <li>",
"     Cooper, DC. Coakley, D, et al. Anti-HBV Activity of Tenofovir Disoproxil Fumarate (TDF) in Lamivudine (LAM) Experienced HIV/HBV Co-Infected. 9th Conference on Retroviruses and Opportunistic Infections; February 24-28, 2002; Seattle, Washington. Abstract 124.",
"    </li>",
"    <li>",
"     Bochet, MR, Benhamou, Y, et al. Tenofovir Disoproxil Fumarate Suppresses Lamivudine Resistant HBV Replication in Patients Co-Infected with HIV/HBV. 9th Conference on Retroviruses and Opportunistic Infections; February 24-28, 2002; Seattle, Washington. Abstract 675.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15321/abstract/74\">",
"      Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359:2442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15321/abstract/75\">",
"      McMahon MA, Jilek BL, Brennan TP, et al. The HBV drug entecavir - effects on HIV-1 replication and resistance. N Engl J Med 2007; 356:2614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15321/abstract/76\">",
"      Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357:2576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15321/abstract/77\">",
"      Gupta SK, Eustace JA, Winston JA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2005; 40:1559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15321/abstract/78\">",
"      Wyatt CM, Murphy B. Kidney transplantation in HIV-infected patients. Semin Dial 2005; 18:495.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7332 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-122.72.76.133-CAE5397922-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_61_15321=[""].join("\n");
var outline_f14_61_15321=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OUTCOMES BEFORE HAART",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Overview of medical literature",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SOLID ORGAN TRANSPLANTATION IN THE HAART ERA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Heart transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CHEMOKINE RECEPTORS, TRANSPLANTATION AND HIV INFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PHARMACOLOGICAL ASPECTS AFTER TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      VIRAL HEPATITIS RECURRENCE AFTER TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      OTHER COMPLICATIONS AFTER SOLID ORGAN TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      CURRENT TRANSPLANT ELIGIBILITY CRITERIA IN THE UNITED STATES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/34/7720?source=related_link\">",
"      Clinical trials of HIV antiretroviral therapy: Integrase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?37/62/38880?source=related_link\">",
"      Cyclosporine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/29/12759?source=related_link\">",
"      Dose modification of antiretroviral agents in adults with renal or hepatic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32424?source=related_link\">",
"      Drug resistance testing in the clinical management of HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/55/7033?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of hepatitis B in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/55/26490?source=related_link\">",
"      Evaluation of the potential renal transplant recipient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/34/5674?source=related_link\">",
"      Immunology of HIV-1 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23030?source=related_link\">",
"      Investigational treatments of chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/5/16474?source=related_link\">",
"      Liver transplantation for hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/53/14170?source=related_link\">",
"      Risk factors for graft failure in kidney transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=related_link\">",
"      Selecting antiretroviral regimens for the treatment naive HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/27/10682?source=related_link\">",
"      Transplantation immunobiology",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_61_15322="Hospital management of older adults";
var content_f14_61_15322=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hospital management of older adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/61/15322/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/61/15322/contributors\">",
"     Melissa Mattison, MD, SFHM",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/61/15322/contributors\">",
"     Edward R Marcantonio, MD, SM",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/61/15322/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/61/15322/contributors\">",
"     Kenneth E Schmader, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/61/15322/contributors\">",
"     Tejal K Gandhi, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/61/15322/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/61/15322/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/61/15322/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H25046683\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients 65 years and older represented 40 percent of hospitalized adults and nearly half of all healthcare dollars spent on hospitalization in 2008, but comprised less than 13 percent of the population in the United States. [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15322/abstract/1\">",
"     1",
"    </a>",
"    ]. Individuals 85 years and older make up only 1.8 percent of the total population but account for 8 percent of all hospital discharges [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15322/abstract/2\">",
"     2",
"    </a>",
"    ]. Hospitalizations and healthcare spending for older adults are expected to rise as the geriatric population grows.",
"   </p>",
"   <p>",
"    The leading non-obstetric diagnoses for adult inpatient stays are pneumonia and cardiovascular diseases, which are both highly prevalent in older adults [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15322/abstract/3\">",
"     3",
"    </a>",
"    ]. Older patients have a longer average length of stay (5.5 days for ages &ge;65 years, compared with 5.0 days for ages 45 to 64 and 3.7 days for ages 15 to 44) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15322/abstract/4\">",
"     4",
"    </a>",
"    ]. With advancing age, patients tend to have increased comorbid chronic illnesses and more disability, making them more vulnerable during hospitalization to adverse events, including nosocomial complications and adverse drug reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15322/abstract/5\">",
"     5",
"    </a>",
"    ]. While most younger patients are discharged to home, 40 percent of patients 85 years and older are discharged to a skilled nursing facility [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15322/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most hospital-based clinicians are not trained to treat older adult patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15322/abstract/6\">",
"     6",
"    </a>",
"    ]. Despite the disproportionate prevalence of hospitalized patients who are in the geriatric age range, hospitalist programs often do not emphasize the need for geriatric skills [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15322/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will discuss common issues related to the management of older hospitalized patients. The medical care of older adults in the outpatient setting and in nursing homes is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/18/38186?source=see_link\">",
"     \"Geriatric health maintenance\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/9/42138?source=see_link\">",
"     \"Medical care of the nursing home patient in the United States\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25046690\">",
"    <span class=\"h1\">",
"     INCREASED VULNERABILITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Older adults have greater vulnerability to acute stress than younger individuals due to age-related diminution of physiologic reserves. This vulnerability is compounded by the greater prevalence of chronic disease (eg, hypertension, chronic kidney disease, and heart failure) in older adults. Measuring physiologic vulnerability in older adults can be challenging. Diminished renal function can be detected with serum creatinine, but quantifying the decline in organ function in other systems, such as the liver, heart, lungs, and brain, is more challenging. Muscle strength and reserve also decline with aging, with detrimental impact on physical function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/24/38282?source=see_link&amp;anchor=H23810845#H23810845\">",
"     \"Normal aging\", section on 'Age-associated physiologic changes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    At baseline, the older adult lives in a state in which organ systems, while functioning with some compromise, are able to sustain life in relative harmony. This state has been termed homeostenosis (",
"    <a class=\"graphic graphic_figure graphicRef58907 \" href=\"UTD.htm?35/21/36178\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15322/abstract/8\">",
"     8",
"    </a>",
"    ].",
"    <em>",
"    </em>",
"    An acute insult or stressor may push one or more organ systems &ldquo;over the brink,&rdquo; resulting in organ failure. When one organ system fails, others often follow. Thus, when an older adult with several chronic medical conditions develops an acute illness, those organ systems that are seemingly unrelated to the presenting problem may lack the reserve to withstand the stresses of the acute illness [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15322/abstract/9\">",
"     9",
"    </a>",
"    ]. The resulting failure of the heart, lungs, kidneys,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    brain (delirium) appears apart from the original complaint for which the patient was hospitalized [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15322/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H657887\">",
"    <span class=\"h1\">",
"     PATIENT ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aging and the cumulative effects of a lifetime of illness allow for a wide range in functional abilities of older adults, such that actual age may not always correlate with physiologic age; some older patients are fully independent while others are not. Thus, it is important to perform a thorough initial patient assessment to understand the patient&rsquo;s physiologic status and functional abilities. The assessment of older hospitalized adults should extend beyond the traditional history and physical examination. In particular, the clinician should assess the patient&rsquo;s physical function, cognition, social supports, and living situation. They should specifically inquire about advanced directives (",
"    <a class=\"graphic graphic_table graphicRef81811 \" href=\"UTD.htm?19/33/19997\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43624?source=see_link\">",
"     \"Comprehensive geriatric assessment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Available tools for inpatient assessment of physical function and the risk of adverse outcomes have relatively poor positive predictive value [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15322/abstract/10\">",
"     10",
"    </a>",
"    ]. Specific risk factors for new onset disability at discharge include age &ge;80 years, dependence in three or more criteria in the assessment of instrumental activities of daily living (IADL) two weeks before admission, poor mobility at baseline (as defined by inability to walk uphill or stairs), severe cognitive impairment, metastatic cancer, and albumin &lt;3",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15322/abstract/11\">",
"     11",
"    </a>",
"    ]. Instruments to be used for the assessment of physical activities of daily living (the Katz index for ADL) and instrumental activities of daily living (the Lawton scale for IADL) are shown in tables (",
"    <a class=\"graphic graphic_table graphicRef66451 \" href=\"UTD.htm?2/13/2269\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef63647 \" href=\"UTD.htm?43/3/44093\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Patients should be asked about substance abuse, including alcohol and nicotine. Additionally, medications should be reviewed in detail to identify unnecessary polypharmacy or dosing problems, including the potential for medication duplication. (See",
"    <a class=\"local\" href=\"#H657914\">",
"     'Medication reconciliation'",
"    </a>",
"    below.) &nbsp;",
"   </p>",
"   <p>",
"    Pain is a common symptom for many older patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15322/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. It is important to consider the impact pain has on daily functioning in older patients and how it may be contributing to the patient&rsquo;s current presentation. Untreated pain can cause delirium, suffering, and inability to participate in prescribed medical therapies. A patient&rsquo;s own report of pain is the best way to determine degree of pain. Understanding whether a patient with advanced cognitive impairment suffers from pain can be challenging, but there are validated tools to aid in this assessment [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15322/abstract/14\">",
"     14",
"    </a>",
"    ]. The American Geriatrics Society has developed guidelines to aid clinicians in assessing and treating older adults with pain [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15322/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H657914\">",
"    <span class=\"h2\">",
"     Medication reconciliation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Up to 30 percent of hospital admissions are the result of adverse drug events [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15322/abstract/16\">",
"     16",
"    </a>",
"    ]. Since older patients often take multiple medications daily and are more vulnerable to adverse drug events, it is particularly important to ensure that a complete and accurate list of medications is obtained at each transition within the hospital setting: on admission, during transfers between hospital wards, and at discharge. Hospital pharmacists can be helpful as a resource for medication reconciliation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/51/30521?source=see_link&amp;anchor=H31685278#H31685278\">",
"     \"Prevention of adverse drug events in hospitals\", section on 'Medication reconciliation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Evaluating the clinical utility of each medication and its potential for side effects or drug interactions is critical to caring for patients&rsquo; acute needs and preventing adverse drug events. Some drugs may be non-prescription, and patients should be specifically queried about use of over-the-counter medications, including complementary or herbal mediation use. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/0/30730?source=see_link\">",
"     \"Drug prescribing for older adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H657921\">",
"    <span class=\"h2\">",
"     Advance directives",
"    </span>",
"    &nbsp;&mdash;&nbsp;A patient's goals, values, and preferences in regard to treatment decisions are particularly relevant during an acute hospitalization, especially in older patients given a larger burden of illness. Inpatient clinicians should know who has been identified as the patient's surrogate decision maker (health care proxy). The patient&rsquo;s desired intensity of care, including goals, values, and preferences regarding resuscitation and artificial respiration, must be clarified with the patient, when possible, or with the healthcare proxy if the patient is not capable of understanding or communicating this information. Understanding these issues will guide which treatments are most appropriate for a given patient.",
"   </p>",
"   <p>",
"    In the case of older patients with underlying dementia or delirium, it becomes important to find a surrogate decision maker quickly to help guide the patient&rsquo;s goals of care. For patients who have not created a health care power of attorney, the spouse or other first-degree relative typically is the default surrogate decision-maker. If no surrogate is designated and next-of-kin is not available, guardianship may be obtained. Guardianship is a legal proceeding whereby the court appoints a surrogate decision-maker. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/8/14473?source=see_link&amp;anchor=H14#H14\">",
"     \"Legal aspects of end of life care\", section on 'Advance directives'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44024?source=see_link\">",
"     \"Ethical issues near the end of life\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H657928\">",
"    <span class=\"h2\">",
"     Social support",
"    </span>",
"    &nbsp;&mdash;&nbsp;An important component of the admission assessment for older patients is inquiry about the patient's home situation and social supports. Multiple aspects of the living situation can impact the health of the older patient (eg, living with family or friends, having part- or full-time help, being in a home versus assisted living facility, the presence of stairs, access to mealtime support). Questionnaires to assess social resources for patients admitted from the community or from a nursing home, adapted from the OARS Multidimensional Functional Assessment Questionnaire, are shown in tables (",
"    <a class=\"graphic graphic_table graphicRef53022 \" href=\"UTD.htm?20/0/20494\">",
"     table 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef64108 \" href=\"UTD.htm?27/53/28510\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15322/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A safe transition at discharge is dependent on an understanding of how the patient manages when not in the hospital. Planning for discharge must begin early in the course of the hospitalization to address all relevant factors and allow ample time to mitigate identified obstacles, thus avoiding unnecessarily prolonged hospitalization. Hospital-based social workers and discharge planners can help address concerns related to medication adherence, home safety, and access to community supports after discharge. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/2/12330?source=see_link\">",
"     \"Hospital discharge\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5404484\">",
"    <span class=\"h2\">",
"     Vaccinations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hospitalization provides an important opportunity to address vaccination status, particularly for pneumococcal and influenza vaccination. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/18/38186?source=see_link&amp;anchor=H9#H9\">",
"     \"Geriatric health maintenance\", section on 'Immunizations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25046739\">",
"    <span class=\"h1\">",
"     PREVENTING SPECIFIC ADVERSE OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hospitalization for the older adult patient can result in unintended adverse consequences from interventions meant to be therapeutic. Bed rest, polypharmacy, tethering devices (eg, intravenous lines, urinary catheters, telemetry, restraints), sensory deprivation, disruption of usual sleep patterns, and lack of proper nutrition all contribute to functional, physical, and cognitive decline [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15322/abstract/18\">",
"     18",
"    </a>",
"    ]. Since many older adults live on the brink between independence and functional dependence, even a small decline in function during hospitalization can place them in a position of newly acquired dependence.",
"   </p>",
"   <p>",
"    Some decline may be unavoidable due to the effects of the acute illness. However, many of the harmful effects of hospitalization can be avoided or minimized by addressing specific risks that predispose to a poor clinical outcome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25046746\">",
"    <span class=\"h2\">",
"     Functional decline",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bed rest and lack of mobility combine to hasten physical deconditioning and muscle weakness [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15322/abstract/19\">",
"     19",
"    </a>",
"    ]. Immobility is associated with increased risk for falls, delirium, skin breakdown, and venous thromboembolic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15322/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although a few conditions require absolute bedrest (eg, unstable fractures and certain critical illnesses), most medical conditions do not necessitate immobility. Activity orders for bed rest should be avoided unless absolutely medically required. Nursing staff should attempt to get patients out of bed to a chair at least twice daily with meals and, when possible, encourage patients to walk.",
"   </p>",
"   <p>",
"    Patients who have difficulty ambulating on their own or who pose a significant fall risk may need supervision by trained staff (eg, physical therapy) or referral to a specialized mobility program. Increased activity during hospitalization can mitigate functional decline so that patients can transition optimally outside the hospital setting [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15322/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H25046837\">",
"     'Early mobilization programs'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31092115\">",
"    <span class=\"h2\">",
"     Falls",
"    </span>",
"    &nbsp;&mdash;&nbsp;Older hospitalized adults are at great risk of falling due to the effects of the acute illness compounded by an unfamiliar environment and side effects of treatments. The etiology of a fall is often multifactorial (",
"    <a class=\"graphic graphic_figure graphicRef63126 \" href=\"UTD.htm?43/9/44190\">",
"     figure 2",
"    </a>",
"    ). Many of the interventions needed to address the acute illness can increase the risk of falling. As an example, interventions to treat an older adult in heart failure (eg, antihypertensive medications, diuretics, telemetry, and an indwelling urinary catheter) all combine to increase the patient&rsquo;s propensity to fall. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/4/22602?source=see_link\">",
"     \"Falls in older persons: Risk factors and patient evaluation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several strategies can help prevent falls in the hospital setting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/59/31673?source=see_link\">",
"     \"Prevention of falls in nursing care facilities and the hospital setting\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The risks and benefits of medications with significant psychotropic and anticholinergic effects (eg, opioid analgesics,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"       diphenhydramine",
"      </a>",
"      ) should be carefully weighed. &nbsp;",
"     </li>",
"     <li>",
"      Patients should be monitored when prescribed drugs that might increase the risk of falls (eg, when diuretics are prescribed, blood pressure and volume status should be monitored closely to avoid orthostatic hypotension).",
"     </li>",
"     <li>",
"      Patients at higher fall risk may need supervision with ambulation.",
"     </li>",
"     <li>",
"      Time out of bed throughout the day should be encouraged, whether walking or sitting in a chair, to prevent orthostatic hypotension associated with prolonged immobility [",
"      <a class=\"abstract\" href=\"UTD.htm?14/61/15322/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Intravenous lines and urinary catheters should be discontinued as early as possible. (See",
"      <a class=\"local\" href=\"#H25046760\">",
"       'Tethers'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Restraints should be avoided since restraints, either physical or pharmacologic, may increase the risk of falling.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Nonetheless, it is likely that the majority of falls that occur in the hospital setting may not actually be preventable. In the United States, Medicare does not reimburse hospitals for complications or extended length of stay related to falls that occur during the course of hospitalization. It is important that institutions not adopt potentially deleterious practices, such as increased use of restraints or restraint-like chairs or other devices, in an effort to decrease their revenue losses [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15322/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31092207\">",
"    <span class=\"h2\">",
"     Delirium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delirium is an acute confusional state marked by inattention and a fluctuating course. The Confusion Assessment Method is frequently used to diagnose delirium (",
"    <a class=\"graphic graphic_table graphicRef69489 \" href=\"UTD.htm?1/48/1804\">",
"     table 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15322/abstract/25\">",
"     25",
"    </a>",
"    ]. An altered level of consciousness",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    disorganized thinking are usual components of delirium. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39081?source=see_link\">",
"     \"Diagnosis of delirium and confusional states\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many aspects of hospitalization promote delirium for the older patient. The change in environment from the comfort of home to a hospital room is disruptive to the patient&rsquo;s daily routine. An older patient, particularly someone with preexisting cognitive impairment, is prone to developing delirium with changes in environment and sensory deprivation. Pain, interruption in sleep patterns, and several classes of medications are important risk factors for delirium (",
"    <a class=\"graphic graphic_table graphicRef70449 \" href=\"UTD.htm?1/11/1214\">",
"     table 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15322/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Confusional states can also be worsened when sensory input is affected, such as occurs when a patient lacks access to eyeglasses or hearing aids.",
"   </p>",
"   <p>",
"    Effective measures to prevent delirium include orientation protocols, environmental modification, nonpharmacologic sleep aids (eg, warm milk or herbal tea offered at bedtime, relaxing music, soft lighting, massage), early mobilization, minimizing use of physical restraints, use of visual and hearing aids, adequate pain treatment, and reduction in polypharmacy (particularly psychoactive drugs) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15322/abstract/28\">",
"     28",
"    </a>",
"    ]. The management of patients with delirium is summarized in an algorithm (",
"    <a class=\"graphic graphic_algorithm graphicRef59337 \" href=\"UTD.htm?9/29/9682\">",
"     algorithm 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/33/28185?source=see_link\">",
"     \"Prevention and treatment of delirium and confusional states\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some hospitals have found that patients with delirium benefit from specialized care delivered in a dedicated room for disoriented patients. This room supports multidisciplinary care that avoids the use of restraints. These &ldquo;delirium rooms&rdquo; can offer a viable option for caring for delirious patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15322/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25046760\">",
"    <span class=\"h2\">",
"     Tethers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some tethering medical devices, such as urinary catheters, intravascular lines, cardiac telemetry leads, and restraints, may be necessary to provide optimal care. However, tethering devices make it more difficult to mobilize patients safely and are associated with increased rates of delirium, infection, and falls [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15322/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. Tethers are commonly ordered when not absolutely indicated, and even when initially appropriate, may remain in place when no longer needed. As an example, despite the well-publicized risks of indwelling urinary catheters, their use and associated complications have not declined over several decades [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15322/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/47/40697?source=see_link&amp;anchor=H4#H4\">",
"     \"Placement and management of urinary bladder catheters\", section on 'Inappropriate use of catheters'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinicians should weigh the risks and benefits of each tethering device and initiate use only when the likelihood of benefit is significant and in keeping with the patient's preferred intensity of care, and there is no effective alternative. As an example, if a patient prefers not to be resuscitated in the event of a cardiac arrest, the benefit of continuous cardiac telemetry should be questioned.",
"   </p>",
"   <p>",
"    There may be options to reduce the total tether burden, such as the use of fluid boluses rather than continuous intravenous fluids. In most cases, urinary catheters should not be used as a treatment for incontinence or as a substitute for getting the patient up to the bathroom.",
"   </p>",
"   <p>",
"    It is important to remove a tether when it is no longer vital for ongoing management. Removing tethers and getting patients out of bed are ways to normalize the daily routine for an older patient. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/22/25962?source=see_link&amp;anchor=H14#H14\">",
"     \"Assessment and management of the acutely agitated or violent adult\", section on 'When to apply restraints'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/9/33941?source=see_link&amp;anchor=H16#H16\">",
"     \"Complications of urinary bladder catheters and preventive strategies\", section on 'Prevention of complications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31578?source=see_link\">",
"     \"Prevention of intravascular catheter-related infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H657213\">",
"    <span class=\"h2\">",
"     Infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Underlying health conditions, poor nutritional status, and greater severity of illness contribute to increased rates of hospital-acquired (or nosocomial) infections in older patients. Heightened clinical suspicion is necessary to identify infection in older patients as they may demonstrate only atypical symptoms, including delirium. Fever may not be present in older patients with an active infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/54/32618?source=see_link\">",
"     \"Evaluation of infection in the older adult\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Commonly seen infections in older hospitalized patients include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Clostridium difficile associated diarrhea",
"      </strong>",
"      &mdash; C. difficile is the most frequent cause of nosocomial diarrhea and a significant cause of morbidity and mortality among hospitalized older patients. The incidence of C. difficile infection continues to rise. Contact precautions have been found to help prevent the spread of C. difficile spores and should be used in patients who have suspected or proven C. difficile infection. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/18/36137?source=see_link&amp;anchor=H3#H3\">",
"       \"Clostridium difficile in adults: Epidemiology, microbiology, and pathophysiology\", section on 'Nosocomial infection'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/57/12184?source=see_link\">",
"       \"Prevention and control of Clostridium difficile in hospital and institutional settings\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Pneumonia",
"      </strong>",
"      &mdash; Hospital-acquired pneumonia (HAP) is pneumonia that occurs 48 hours or more after admission. The most significant risk factor for hospital-acquired pneumonia is mechanical ventilation. Patients with advanced dementia, severe Parkinson disease, or other neurologic conditions, are also at high risk for aspiration pneumonia.",
"      <br/>",
"      <br/>",
"      Preventive measures include avoidance of acid-blocking medications, attention to oral hygiene, and feeding only when the patient is alert and able to sit upright [",
"      <a class=\"abstract\" href=\"UTD.htm?14/61/15322/abstract/34,35\">",
"       34,35",
"      </a>",
"      ]. Patients who cough when swallowing may be showing signs of swallowing dysfunction and aspiration. Offering increased assistance with feeding, modified consistency of foods, and a formal swallowing assessment may be warranted. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/57/12183?source=see_link\">",
"       \"Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13433?source=see_link\">",
"       \"Risk factors and prevention of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31017?source=see_link\">",
"       \"Aspiration pneumonia in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Urinary tract infections",
"      </strong>",
"      &mdash; Urinary tract infections associated with urinary catheters are the leading cause of secondary nosocomial bacteremia, which is associated with high mortality. Patients with indwelling catheters often do not experience typical signs of urinary tract infection. Blood and urine cultures should be obtained when patients develop fever or otherwise unexplained systemic manifestations compatible with infection (eg, altered mental status, fall in blood pressure, metabolic acidosis, and respiratory alkalosis).",
"      <br/>",
"      <br/>",
"      The most effective strategies to reduce urinary infections are avoidance of unnecessary catheterization and catheter removal when the catheter is no longer indicated. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/24/44422?source=see_link\">",
"       \"Urinary tract infection associated with urethral catheters\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/9/33941?source=see_link&amp;anchor=H16#H16\">",
"       \"Complications of urinary bladder catheters and preventive strategies\", section on 'Prevention of complications'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Intravascular catheter-related infections",
"      </strong>",
"      &mdash; Intravascular catheter infections are an important cause of morbidity and mortality. Several preventive measures, such as wiping access sites with antiseptic and connecting only to sterile devices, can markedly reduce the rate of intravascular catheter infections (",
"      <a class=\"graphic graphic_table graphicRef75251 \" href=\"UTD.htm?32/35/33340\">",
"       table 8",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31578?source=see_link\">",
"       \"Prevention of intravascular catheter-related infections\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Infection control programs aim to prevent and reduce rates of nosocomial infections. Major components of infection control are (",
"    <a class=\"graphic graphic_table graphicRef50001 \" href=\"UTD.htm?24/18/24877\">",
"     table 9",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Standard (universal) precautions",
"     </li>",
"     <li>",
"      Isolation precautions when appropriate, with recognition that isolation may increase the risk of delirium in older adults",
"     </li>",
"     <li>",
"      Environmental cleaning",
"     </li>",
"     <li>",
"      Surveillance",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Standard precautions are recommended in the care of all hospitalized patients to reduce the risk of infection transmission between patients and healthcare workers, even when the presence of an infectious agent is not apparent. Precautions include hand hygiene before and after every patient contact (",
"    <a class=\"graphic graphic_table graphicRef77676 \" href=\"UTD.htm?14/28/14795\">",
"     table 10",
"    </a>",
"    ); use of gloves, gowns, and eye protection for situations in which exposure to body fluids is possible; and safe disposal of sharp instruments in impervious containers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/53/8026?source=see_link&amp;anchor=H3#H3\">",
"     \"Epidemiology of methicillin-resistant Staphylococcus aureus infection in adults\", section on 'Healthcare-associated methicillin-resistant Staphylococcus aureus'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27721?source=see_link\">",
"     \"Epidemiology, prevention and control of vancomycin-resistant enterococci\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19658?source=see_link\">",
"     \"General principles of infection control\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31092339\">",
"    <span class=\"h2\">",
"     Malnutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Poor nutrition for older hospitalized patients may result from several factors:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Impaired cognition or delirium",
"     </li>",
"     <li>",
"      Poor appetite, nausea, or constipation (due to underlying illness or as side effects of medications)",
"     </li>",
"     <li>",
"      Restriction of movement (see",
"      <a class=\"local\" href=\"#H25046760\">",
"       'Tethers'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      No access to dentures",
"     </li>",
"     <li>",
"      Difficulty in self-feeding",
"     </li>",
"     <li>",
"      Severely restricted diet orders (eg, NPO)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Evaluation for malnutrition includes a history of changes in weight, dietary intake, and physical examination, as well as select laboratory and radiologic studies. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/12/31946?source=see_link\">",
"     \"Geriatric nutrition: Nutritional issues in older adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Simple interventions such as getting an older patient out of bed at mealtime and providing assistance with feeding can improve nutritional intake during hospitalization. In-patient assessment by a nutritionist can identify nutritional deficiencies in older patients and, combined with subsequent nutritional follow-up in the community following discharge, may decrease mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15322/abstract/36\">",
"     36",
"    </a>",
"    ]. Patients should be allowed to eat unless medically required to be maintained &ldquo;nothing by mouth&rdquo; (NPO). Generally, severely restricted diets are not required for older patients and when ordered may further limit the nutritional intake of older patients.",
"   </p>",
"   <p>",
"    Nutritional repletion may be provided to restore the patient to a target weight, with recognition that weight correction in the older population is less readily accomplished than in younger people. A meta-analysis of 15 studies in malnourished geriatric patients (including some patients in hospital, as well as nursing home, settings) found a small survival advantage for patients provided with liquid diet supplements compared to no specific nutrition treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15322/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/12/31946?source=see_link&amp;anchor=H17#H17\">",
"     \"Geriatric nutrition: Nutritional issues in older adults\", section on 'Treatment of weight loss'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13831?source=see_link\">",
"     \"Nutrition support in critically ill patients: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several issues should be considered before placement of a feeding tube, particularly in older patients with multiple morbidities. Whenever possible, oral feedings are preferred to the use of feeding tubes. The patient and family should be counseled and their wishes known prior to inserting a feeding tube. Feeding tubes have not been demonstrated to prolong survival in patients with dementia, nor have they been shown to provide improved comfort at the end of life [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15322/abstract/38\">",
"     38",
"    </a>",
"    ]. If the patient or their proxy elects to have a feeding tube, the tube should be removed when the patient is able to take nutrition orally, or when tube feeding is no longer consistent with the patient&rsquo;s care plan. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/17/34073?source=see_link&amp;anchor=H2#H2\">",
"     \"Nutrition support in critically ill patients: Enteral nutrition\", section on 'Indications and contraindications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/51/33592?source=see_link&amp;anchor=H2#H2\">",
"     \"Enteral feeding: Gastric versus post-pyloric\", section on 'Issues for deciding upon the type of enteral nutrition'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25046781\">",
"    <span class=\"h2\">",
"     Pressure ulcers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several host and environmental factors increase the risk of developing pressure ulcers during hospitalization in older patients, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Poor nutritional status",
"     </li>",
"     <li>",
"      Incontinence, causing a moist environment",
"     </li>",
"     <li>",
"      Immobility",
"     </li>",
"     <li>",
"      Neurologic impairment",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/20/34120?source=see_link\">",
"     \"Pressure ulcers: Epidemiology, pathogenesis, clinical manifestations, and staging\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Optimizing nutritional status and limiting time spent in one position can help prevent pressure ulcers. Patients who are bed-bound should be repositioned at least every two hours, with proper repositioning techniques to minimize shear forces. Pressure-reducing products for patients at increased risk of ulcers should also be used. Clinical risk assessment and preventive interventions are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/1/1049?source=see_link\">",
"     \"Prevention of pressure ulcers\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25046788\">",
"    <span class=\"h2\">",
"     Venous thromboembolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hospitalization is a significant risk factor for developing venous thromboembolism [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15322/abstract/20\">",
"     20",
"    </a>",
"    ]. The use of prophylaxis for venous thromboembolic disease, including pharmacologic or mechanical methods, depends on the individual risk of thrombosis and bleeding. Prophylactic anticoagulation should be used for most patients &gt;75 years of age who are hospitalized for an acute illness and who do not have risk factors for increased bleeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/21/36186?source=see_link\">",
"     \"Prevention of venous thromboembolic disease in medical patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31091992\">",
"    <span class=\"h2\">",
"     Adverse drug events",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serious adverse drug events include delirium, urinary retention, orthostasis, metabolic derangements, bleeding from anticoagulation, and hypoglycemia related to medications for diabetes. Gastrointestinal side effects, including nausea, anorexia, dysphagia, and constipation, are common. Adverse drug events increase the length of stay and costs of care.",
"   </p>",
"   <p>",
"    Several high-risk drugs are commonly associated with adverse drug events in hospitalized patients (",
"    <a class=\"graphic graphic_table graphicRef51353 \" href=\"UTD.htm?30/2/30765\">",
"     table 11",
"    </a>",
"    ). Multiple medications, often new to the patient during hospitalization, potentiate the risk of nutritional, functional, and cognitive decline in older adults during hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15322/abstract/39\">",
"     39",
"    </a>",
"    ], as well as increase the risk of overall mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15322/abstract/40\">",
"     40",
"    </a>",
"    ]. With physiologic decreases in liver and kidney function, older patients have a higher incidence of adverse drug events than younger patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/0/30730?source=see_link\">",
"     \"Drug prescribing for older adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/51/30521?source=see_link&amp;anchor=H531415754#H531415754\">",
"     \"Prevention of adverse drug events in hospitals\", section on 'High-risk populations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Minimizing the use of nonessential medications can reduce the risk that an older patient will suffer from an adverse drug event. Avoiding potentially inappropriate medication and starting with the smallest possible therapeutic dose can similarly help avoid adverse drug events. Older patients who have impaired renal or hepatic function should have dosage of medications (eg, antibiotics) adjusted appropriately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/51/30521?source=see_link&amp;anchor=H671616258#H671616258\">",
"     \"Prevention of adverse drug events in hospitals\", section on 'Interventions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25046802\">",
"    <span class=\"h1\">",
"     HOSPITAL-WIDE INTERVENTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although limitations in the physiologic reserve for older patients are largely not modifiable, there are several strategies that can improve outcomes for older adults when implemented on a hospital-wide basis. Many of these interventions are based upon preventive interventions for individual adverse outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25046809\">",
"    <span class=\"h2\">",
"     Multidisciplinary team",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multidisciplinary hospital teams strive to integrate all care providers into the daily assessment and plan of care for older patients. Including input from the attending physician, geriatrician, nursing staff,",
"    <span class=\"nowrap\">",
"     physical/occupational/speech",
"    </span>",
"    therapists, outpatient providers, social worker, and discharge staff, combined with input from the patient and family, can enhance the quality of care provided to the complex, older hospitalized patient. Components of effective multidisciplinary teams include localization of physicians, daily goals of care forms and checklists, and interdisciplinary rounds [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15322/abstract/41\">",
"     41",
"    </a>",
"    ]. The benefits of multidisciplinary care have been demonstrated in patients hospitalized for hip fractures, in particular, where patients who received multidisciplinary care with involvement of geriatric medical experts experienced shorter length of stays and lower rates of complications, including delirium [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15322/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One model for multidisciplinary care involves dedicated staff in a designated geriatric unit within the hospital. (See",
"    <a class=\"local\" href=\"#H27349052\">",
"     'Geriatric units'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Since not all hospitals have the resources to provide specialized units for older patients, some programs have attempted to re-create the core elements of multidisciplinary care units for hospitalized older persons who are not located on a single unit [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15322/abstract/44\">",
"     44",
"    </a>",
"    ]. Whether these \"virtual\" units are as effective as traditional geriatric units is unknown. The lack of a consistent nursing staff trained in the care of older persons may diminish the effectiveness of this model. Other hospitals have combined hospitalist-directed care with mobile geriatric care teams to provide enhanced care to older patients throughout the hospital [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15322/abstract/45\">",
"     45",
"    </a>",
"    ]. In a trial comparing hospitalized patients age &gt;70 assigned to an intervention involving an interdisciplinary geriatric team or usual care, patients who were assigned the intervention were more likely to have &ldquo;do not resuscitate orders&rdquo; and more likely to be recognized with cognitive",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    functional status impairments, but there was no difference in outcomes such as length of stay or readmission rates, or in falls, use of restraints, or sleeping medications [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15322/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Hospital Elder Life Program (HELP) demonstrated that skilled staff and volunteers could implement targeted, practical interventions including reorientation, cognitive stimulation, and non-pharmacological sleep protocols [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15322/abstract/47\">",
"     47",
"    </a>",
"    ]. HELP programs may decrease rates of delirium, reduce length of stay, improve patient satisfaction, and reduce hospital costs [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15322/abstract/48,49\">",
"     48,49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25046830\">",
"    <span class=\"h2\">",
"     Checklists and order sets",
"    </span>",
"    &nbsp;&mdash;&nbsp;Checklists can improve quality of care for older patients by integrating reminders into every day care to ensure practice standards are met [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15322/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. Checklists can be tailored to remind staff about specific geriatric issues such as daily patient mobilization, readdressing the need for tethers, and assessing for the presence of delirium.",
"   </p>",
"   <p>",
"    Defined admission order sets have been shown to improve adherence with venous thromboembolism prophylaxis and may also address some of the most common concerns affecting older patients, including diet, medications, and advance directives [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15322/abstract/52\">",
"     52",
"    </a>",
"    ]. As an example, clinicians can select a default activity order that directs nursing staff to get patients out of bed at least twice daily, rather than the more common nonspecific order of activity: &ldquo;ad lib.&rdquo;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25046837\">",
"    <span class=\"h2\">",
"     Early mobilization programs",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to ensure that patients are mobilized early and often during their hospitalization. Mobilization can help prevent falls [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15322/abstract/53\">",
"     53",
"    </a>",
"    ]. Observational studies find that increased mobility in the hospital is associated with less functional decline during hospitalization and shorter lengths of stay [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15322/abstract/54,55\">",
"     54,55",
"    </a>",
"    ], though whether this represents a healthier population rather than the impact of mobilization is uncertain in the absence of data from a prospective trial. Evidence suggests that even ventilated patients in the intensive care unit (ICU) can benefit from early mobilization programs [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15322/abstract/56\">",
"     56",
"    </a>",
"    ]. Early mobilization after acute stroke is also associated with improved functional outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15322/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hospital-based mobilization programs are an ideal way to ensure that patients are getting out of bed and maintaining some mobility and function during their acute illness. Younger patients may be encouraged to mobilize independently, but most older patients will require assistance to safely navigate out of bed, especially if one or more tethers are present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25046844\">",
"    <span class=\"h2\">",
"     Safety equipment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many hospitals rely upon specially developed safety devices to monitor patients for falls, including alarms integrated into patient beds and chairs to notify nursing staff when a patient attempts to rise unassisted. These alarms have not been rigorously shown to prevent falls or improve overall care of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15322/abstract/58\">",
"     58",
"    </a>",
"    ]. Beds that are positioned lower to the ground, or at floor-level, have been used to lessen the potential height that a patient may fall when the patient rises from bed. Although this theoretically may limit the risk of severe injury, these &ldquo;low beds&rdquo; have also not been shown to limit injury or improve safety [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15322/abstract/59\">",
"     59",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/59/31673?source=see_link&amp;anchor=H17785970#H17785970\">",
"     \"Prevention of falls in nursing care facilities and the hospital setting\", section on 'Restraints and alarms'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12189663\">",
"    <span class=\"h1\">",
"     SITES OF CARE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25046851\">",
"    <span class=\"h2\">",
"     Intensive care in critical illness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients 65 years and older account for 40 percent of patients in the intensive care unit (ICU) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15322/abstract/60\">",
"     60",
"    </a>",
"    ]. Age alone does not predict survival from a critical medical illness, even in the most vulnerable older patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15322/abstract/61\">",
"     61",
"    </a>",
"    ]. The most important factor in determining if the ICU is appropriate for an older patient is consideration whether or not intensive care is congruent with an individual patient&rsquo;s care wishes. Ambiguous advance directives can make this difficult, especially during the acute presentation, highlighting the importance of proactively addressing goals of care [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15322/abstract/62\">",
"     62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/7/32887?source=see_link\">",
"     \"Ethics in the intensive care unit: Withholding and withdrawing life-support\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If resuscitation and artificial respiration are acceptable, the clinician should keep in mind that the selection of medications for anesthesia and the approach to bag masking and intubation may vary in older adults. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/48/11014?source=see_link\">",
"     \"Emergency airway management in the geriatric patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27349052\">",
"    <span class=\"h2\">",
"     Geriatric units",
"    </span>",
"    &nbsp;&mdash;&nbsp;While not available at all hospitals, medical units dedicated specifically to the multidisciplinary care of older patients can improve functional status and reduce the frequency of discharge to long-term care facilities [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15322/abstract/63\">",
"     63",
"    </a>",
"    ]. Several inpatient geriatric unit approaches have been developed in a variety of clinical settings [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15322/abstract/64\">",
"     64",
"    </a>",
"    ]. Within the Department of Veterans Affairs Hospitals in the US, these are usually referred to as Geriatric Evaluation and Management Units (GEMUs). In academic and private sector hospitals, they are usually labeled Acute Care of the Elderly (ACE) units. ACE units initially included structural modifications to promote mobility and simulate living conditions at home in preparation for a return to independence. More recently, however, ACE units are located on conventional hospital wards as designated geriatric units. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43624?source=see_link&amp;anchor=H19#H19\">",
"     \"Comprehensive geriatric assessment\", section on 'Acute geriatric care units'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One meta-analysis of 17 randomized trials evaluating geriatric rehabilitative units (within an acute care hospital or a rehabilitation hospital) found that inpatient multidisciplinary programs were associated with improvement in all outcomes at discharge, including better functional status (OR 1.75, 95% CI 1.31-2.35), decreased nursing home admission (RR 0.64, 0.51-0.81), and reduced mortality (RR 0.72, 0.55-0.95) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15322/abstract/65\">",
"     65",
"    </a>",
"    ]. Another meta-analysis of 22 randomized trials found that hospitalized patients receiving comprehensive geriatric evaluation in a geriatric unit were more likely to be alive and in their homes during at 6- and 12-month follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15322/abstract/66\">",
"     66",
"    </a>",
"    ]. This meta-analysis was limited by wide variability in interventions across trials.",
"   </p>",
"   <p>",
"    These geriatric units rely upon team-based care as well as staffing and environmental modifications to the unit to address some of the difficulties older adults face during hospitalization. However, due to a longer length of stay (up to three months), such rehabilitative units are rarely available in the United States outside of the Department of Veterans Affairs hospitals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12189686\">",
"    <span class=\"h2\">",
"     Alternatives to hospital care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hospitalization is disruptive for all individuals, but particularly so for medically complex older patients. Additionally, older patients are particularly vulnerable to medical errors that occur during transitions of care [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15322/abstract/67\">",
"     67",
"    </a>",
"    ]. Avoiding hospitalization and providing care within the patient&rsquo;s home environment can sometimes meet the medical needs of the patient, as well as align with the patient&rsquo;s goals of care around intensity of treatment.",
"   </p>",
"   <p>",
"    Only patients who require care that can be uniquely provided in the hospital should be admitted. For selected patients, home health services or care within nursing homes may provide enough support for older adults with an illness such as pneumonia or a urinary tract infection. If such services align with the patient&rsquo;s desired intensity of care and are medically appropriate, the hazards of hospitalization can be avoided.",
"   </p>",
"   <p>",
"    Unfortunately, current reimbursement rules in the United States often prevent the mobilization of adequate resources in the home environment to allow hospital-level care in the home to be a viable option.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25046865\">",
"    <span class=\"h1\">",
"     PALLIATIVE CARE/COMFORT-FOCUSED CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines have been suggested to help clinicians identify patients at the time of hospital admission who might benefit from palliative care (",
"    <a class=\"graphic graphic_table graphicRef76969 \" href=\"UTD.htm?30/62/31724\">",
"     table 12",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef51669 \" href=\"UTD.htm?36/16/37131\">",
"     table 13",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15322/abstract/68\">",
"     68",
"    </a>",
"    ]. Larger hospitals often have special palliative care teams to provide care to this population. It is critical to minimize medications and treatments that are perceived as burdensome to the patient who has chosen care with a focus on comfort. Providers should identify patients suffering from pain or other troublesome symptoms (eg, confusion, constipation, nausea, and dyspnea) and work to address these symptoms to improve comfort.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25046872\">",
"    <span class=\"h1\">",
"     DISCHARGE PLANNING",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the transition from hospital to home or skilled nursing facility, older patients are particularly vulnerable to medication errors and confusion about follow-up care. It is increasingly rare for a single clinician to provide both inpatient and outpatient care, which further increases the challenges of maintaining high-quality care during this transition [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15322/abstract/67\">",
"     67",
"    </a>",
"    ]. While most younger patients are discharged to home, 40 percent of patients 85 years and older are discharged to a skilled nursing facility prior to going home, which adds a second transition and a third set of care providers [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15322/abstract/1\">",
"     1",
"    </a>",
"    ]. Moreover, due to higher rates of cognitive impairment, older adults may be less able than younger patients to participate actively in their discharge plan of care. Little data are available demonstrating that discharge interventions prevent hospital readmission [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15322/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinicians and others working with older patients at the time of discharge should strongly consider partnering with the patient&rsquo;s family or other social supports to increase the likelihood that the care transition will go smoothly. A discharge checklist can be particularly helpful to ensure that the clinician covers the most salient issues for a smooth transition out of the hospital (",
"    <a class=\"graphic graphic_table graphicRef54279 \" href=\"UTD.htm?14/44/15053\">",
"     table 14",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/61/15322/abstract/50\">",
"     50",
"    </a>",
"    ]. Select interventions at discharge, such as medication reconciliation and educational programs, may help prevent readmission. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/2/12330?source=see_link\">",
"     \"Hospital discharge\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several programs have been developed to improve the hospital discharge process, including Project BOOST (",
"    <a class=\"external\" href=\"file://www.hospitalmedicine.org/BOOST\">",
"     www.hospitalmedicine.org/BOOST",
"    </a>",
"    ) and the Care Transitions Program (",
"    <a class=\"external\" href=\"file://www.caretransitions.org/\">",
"     www.caretransitions.org",
"    </a>",
"    ). These, and similar initiatives, are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/2/12330?source=see_link&amp;anchor=H23#H23\">",
"     \"Hospital discharge\", section on 'Multiple interventions'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/16/34050?source=see_link\">",
"       \"Patient information: Going home from the hospital (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25046879\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Older adults represent a large and growing segment of hospitalized patients and are at high risk of complications during hospitalization, including falls, delirium, adverse drug events, infections, and death. (See",
"      <a class=\"local\" href=\"#H25046683\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H25046690\">",
"       'Increased vulnerability'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The assessment of older hospitalized adults should extend beyond the traditional history and physical to include assessment of physical function and cognition, social supports, and living situation as well as evaluation for possible polypharmacy and attention to advance directives (",
"      <a class=\"graphic graphic_table graphicRef81811 \" href=\"UTD.htm?19/33/19997\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H657887\">",
"       'Patient assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Since many older adults live on the brink between independence and functional dependence, even a small decline in function during hospitalization can place them in a position of newly-acquired dependence. However, many adverse outcomes encountered by older adults during hospitalization can be prevented (see",
"      <a class=\"local\" href=\"#H25046739\">",
"       'Preventing specific adverse outcomes'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Activity orders for bed rest should be avoided unless absolutely required. Patients who have difficulty ambulating on their own or pose a significant fall risk may need supervision (eg, nurse, physical therapy).",
"     </li>",
"     <li>",
"      All tethers should be avoided whenever possible, including urinary catheters, intravascular lines, cardiac telemetry leads, and physical restraints.",
"     </li>",
"     <li>",
"      Effective measures to prevent delirium include orientation protocols, environmental modification, nonpharmacologic sleep aids, early mobilization, use of visual and hearing aids, adequate pain treatment, and reduction in polypharmacy (particularly psychoactive drugs) (",
"      <a class=\"graphic graphic_algorithm graphicRef59337 \" href=\"UTD.htm?9/29/9682\">",
"       algorithm 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Standard precautions are recommended in the care of all hospitalized patients, including hand hygiene before and after every patient contact (",
"      <a class=\"graphic graphic_table graphicRef77676 \" href=\"UTD.htm?14/28/14795\">",
"       table 10",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Simple interventions such as getting an older patient out of bed at mealtime and providing assistance are important in maximizing nutritional intake.",
"     </li>",
"     <li>",
"      Limiting time spent in one position can help prevent pressure ulcers. Bedbound patients should be repositioned at least every two hours, with proper repositioning techniques to minimize shear forces.",
"     </li>",
"     <li>",
"      Minimizing the use of non-essential medications can reduce the risk of an adverse drug event. Avoiding high-risk drugs (",
"      <a class=\"graphic graphic_table graphicRef51353 \" href=\"UTD.htm?30/2/30765\">",
"       table 11",
"      </a>",
"      ) and starting with the smallest possible therapeutic dose can similarly help avoid adverse drug events.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some hospital-wide strategies are associated with improved outcomes for older adults, including care involving multidisciplinary teams, checklists, and early mobilization programs. (See",
"      <a class=\"local\" href=\"#H25046802\">",
"       'Hospital-wide interventions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most important factor in determining if the ICU is appropriate for an older patient is to consider whether or not intensive care is congruent with an individual patient&rsquo;s care wishes. (See",
"      <a class=\"local\" href=\"#H25046851\">",
"       'Intensive care in critical illness'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Older patients are particularly vulnerable to medication errors and confusion about follow-up care. A discharge checklist can be particularly helpful to ensure that the clinician covers the most salient issues for a smooth transition out of the hospital (",
"      <a class=\"graphic graphic_table graphicRef54279 \" href=\"UTD.htm?14/44/15053\">",
"       table 14",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H25046872\">",
"       'Discharge planning'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Healthcare Cost and Utilization Project Facts and Figures 2008. Statistics on Hospital-Based Care in the United States. Agency for Healthcare Research and Quality (AHRQ). file://www.hcup-us.ahrq.gov/reports/factsandfigures/2008/section1_TOC.jsp.",
"    </li>",
"    <li>",
"     Wier L, Pfuntner A, Steiner C. Hospital Utilization among Oldest Adults, 2008: Statistical Brief #103. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs; Agency for Health Care Policy and Research, Rockville, MD 2010.",
"    </li>",
"    <li>",
"     file://www.hcup-us.ahrq.gov/reports/factsandfigures/2008/exhibit2_1.jsp (Accessed on October 07, 2011).",
"    </li>",
"    <li>",
"     file://www.cdc.gov/nchs/data/series/sr_13/sr13_165.pdf#table1 (Accessed on October 07, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15322/abstract/5\">",
"      Marengoni A, Winblad B, Karp A, Fratiglioni L. Prevalence of chronic diseases and multimorbidity among the elderly population in Sweden. Am J Public Health 2008; 98:1198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15322/abstract/6\">",
"      Landefeld CS. Care of hospitalized older patients: opportunities for hospital-based physicians. J Hosp Med 2006; 1:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15322/abstract/7\">",
"      Wald H, Huddleston J, Kramer A. Is there a geriatrician in the house? Geriatric care approaches in hospitalist programs. J Hosp Med 2006; 1:29.",
"     </a>",
"    </li>",
"    <li>",
"     Fries JF, Crapo LM. Vitality and aging: Implications of a rectangular curve, W.H. Freeman and Company, San Franscisco and Oxford 1981.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15322/abstract/9\">",
"      Resnick NM, Marcantonio ER. How should clinical care of the aged differ? Lancet 1997; 350:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15322/abstract/10\">",
"      De Saint-Hubert M, Schoevaerdts D, Cornette P, et al. Predicting functional adverse outcomes in hospitalized older patients: a systematic review of screening tools. J Nutr Health Aging 2010; 14:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15322/abstract/11\">",
"      Mehta KM, Pierluissi E, Boscardin WJ, et al. A clinical index to stratify hospitalized older adults according to risk for new-onset disability. J Am Geriatr Soc 2011; 59:1206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15322/abstract/12\">",
"      Thomas E, Peat G, Harris L, et al. The prevalence of pain and pain interference in a general population of older adults: cross-sectional findings from the North Staffordshire Osteoarthritis Project (NorStOP). Pain 2004; 110:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15322/abstract/13\">",
"      Helme RD, Gibson SJ. The epidemiology of pain in elderly people. Clin Geriatr Med 2001; 17:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15322/abstract/14\">",
"      Chibnall JT, Tait RC. Pain assessment in cognitively impaired and unimpaired older adults: a comparison of four scales. Pain 2001; 92:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15322/abstract/15\">",
"      American Geriatrics Society Panel on Pharmacological Management of Persistent Pain in Older Persons. Pharmacological management of persistent pain in older persons. J Am Geriatr Soc 2009; 57:1331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15322/abstract/16\">",
"      Chan M, Nicklason F, Vial JH. Adverse drug events as a cause of hospital admission in the elderly. Intern Med J 2001; 31:199.",
"     </a>",
"    </li>",
"    <li>",
"     OARS Multidimensional Functional Assessment Questionnaire. Older Americans Resources and Services Program of the Duke University Center for the Study of Aging and Human Development. 1975, revised 1988. Durham, NC.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15322/abstract/18\">",
"      Creditor MC. Hazards of hospitalization of the elderly. Ann Intern Med 1993; 118:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15322/abstract/19\">",
"      Corcoran PJ. Use it or lose it--the hazards of bed rest and inactivity. West J Med 1991; 154:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15322/abstract/20\">",
"      Heit JA, Silverstein MD, Mohr DN, et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000; 160:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15322/abstract/21\">",
"      Campbell AJ, Borrie MJ, Spears GF. Risk factors for falls in a community-based prospective study of people 70 years and older. J Gerontol 1989; 44:M112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15322/abstract/22\">",
"      Graf C. Functional decline in hospitalized older adults. Am J Nurs 2006; 106:58.",
"     </a>",
"    </li>",
"    <li>",
"     Mohrman DE, Heller LJ. Cardiovascular Physiology, 7th ed, McGraw-Hill, 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15322/abstract/24\">",
"      Inouye SK, Brown CJ, Tinetti ME. Medicare nonpayment, hospital falls, and unintended consequences. N Engl J Med 2009; 360:2390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15322/abstract/25\">",
"      Inouye SK, van Dyck CH, Alessi CA, et al. Clarifying confusion: the confusion assessment method. A new method for detection of delirium. Ann Intern Med 1990; 113:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15322/abstract/26\">",
"      Flaherty JH. Insomnia among hospitalized older persons. Clin Geriatr Med 2008; 24:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15322/abstract/27\">",
"      Vaurio LE, Sands LP, Wang Y, et al. Postoperative delirium: the importance of pain and pain management. Anesth Analg 2006; 102:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15322/abstract/28\">",
"      Inouye SK, Bogardus ST Jr, Charpentier PA, et al. A multicomponent intervention to prevent delirium in hospitalized older patients. N Engl J Med 1999; 340:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15322/abstract/29\">",
"      Flaherty JH, Tariq SH, Raghavan S, et al. A model for managing delirious older inpatients. J Am Geriatr Soc 2003; 51:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15322/abstract/30\">",
"      Sax H, Hugonnet S, Harbarth S, et al. Variation in nosocomial infection prevalence according to patient care setting:a hospital-wide survey. J Hosp Infect 2001; 48:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15322/abstract/31\">",
"      Albert NM, Hancock K, Murray T, et al. Cleaned, ready-to-use, reusable electrocardiographic lead wires as a source of pathogenic microorganisms. Am J Crit Care 2010; 19:e73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15322/abstract/32\">",
"      Alagiakrishnan K, Marrie T, Rolfson D, et al. Gaps in patient care practices to prevent hospital-acquired delirium. Can Fam Physician 2009; 55:e41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15322/abstract/33\">",
"      Holroyd-Leduc JM, Sen S, Bertenthal D, et al. The relationship of indwelling urinary catheters to death, length of hospital stay, functional decline, and nursing home admission in hospitalized older medical patients. J Am Geriatr Soc 2007; 55:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15322/abstract/34\">",
"      Quagliarello V, Ginter S, Han L, et al. Modifiable risk factors for nursing home-acquired pneumonia. Clin Infect Dis 2005; 40:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15322/abstract/35\">",
"      Herzig SJ, Howell MD, Ngo LH, Marcantonio ER. Acid-suppressive medication use and the risk for hospital-acquired pneumonia. JAMA 2009; 301:2120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15322/abstract/36\">",
"      Feldblum I, German L, Castel H, et al. Individualized nutritional intervention during and after hospitalization: the nutrition intervention study clinical trial. J Am Geriatr Soc 2011; 59:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15322/abstract/37\">",
"      Koretz RL, Avenell A, Lipman TO, et al. Does enteral nutrition affect clinical outcome? A systematic review of the randomized trials. Am J Gastroenterol 2007; 102:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15322/abstract/38\">",
"      Gillick MR. Rethinking the role of tube feeding in patients with advanced dementia. N Engl J Med 2000; 342:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15322/abstract/39\">",
"      Jyrkk&auml; J, Enlund H, Lavikainen P, et al. Association of polypharmacy with nutritional status, functional ability and cognitive capacity over a three-year period in an elderly population. Pharmacoepidemiol Drug Saf 2011; 20:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15322/abstract/40\">",
"      Jyrkk&auml; J, Enlund H, Korhonen MJ, et al. Polypharmacy status as an indicator of mortality in an elderly population. Drugs Aging 2009; 26:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15322/abstract/41\">",
"      O'Leary KJ, Sehgal NL, Terrell G, et al.. Interdisciplinary teamwork in hospitals A review and practical recommendations for improvement. J Hosp Med 2012; 7:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15322/abstract/42\">",
"      Vid&aacute;n M, Serra JA, Moreno C, et al. Efficacy of a comprehensive geriatric intervention in older patients hospitalized for hip fracture: a randomized, controlled trial. J Am Geriatr Soc 2005; 53:1476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15322/abstract/43\">",
"      Marcantonio ER, Flacker JM, Wright RJ, Resnick NM. Reducing delirium after hip fracture: a randomized trial. J Am Geriatr Soc 2001; 49:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15322/abstract/44\">",
"      Arbaje AI, Maron DD, Yu Q, et al. The geriatric floating interdisciplinary transition team. J Am Geriatr Soc 2010; 58:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15322/abstract/45\">",
"      Farber JI, Korc-Grodzicki B, Du Q, et al. Operational and quality outcomes of a mobile acute care for the elderly service. J Hosp Med 2011; 6:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15322/abstract/46\">",
"      Wald HL, Glasheen JJ, Guerrasio J, et al. Evaluation of a hospitalist-run acute care for the elderly service. J Hosp Med 2011; 6:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15322/abstract/47\">",
"      Inouye SK, Bogardus ST Jr, Baker DI, et al. The Hospital Elder Life Program: a model of care to prevent cognitive and functional decline in older hospitalized patients. Hospital Elder Life Program. J Am Geriatr Soc 2000; 48:1697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15322/abstract/48\">",
"      Rubin FH, Neal K, Fenlon K, et al. Sustainability and scalability of the hospital elder life program at a community hospital. J Am Geriatr Soc 2011; 59:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15322/abstract/49\">",
"      Mouchoux C, Rippert P, Duclos A, et al. Impact of a multifaceted program to prevent postoperative delirium in the elderly: the CONFUCIUS stepped wedge protocol. BMC Geriatr 2011; 11:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15322/abstract/50\">",
"      Halasyamani L, Kripalani S, Coleman E, et al. Transition of care for hospitalized elderly patients--development of a discharge checklist for hospitalists. J Hosp Med 2006; 1:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15322/abstract/51\">",
"      Pronovost P, Needham D, Berenholtz S, et al. An intervention to decrease catheter-related bloodstream infections in the ICU. N Engl J Med 2006; 355:2725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15322/abstract/52\">",
"      O'Connor C, Adhikari NK, DeCaire K, Friedrich JO. Medical admission order sets to improve deep vein thrombosis prophylaxis rates and other outcomes. J Hosp Med 2009; 4:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15322/abstract/53\">",
"      Chang JT, Morton SC, Rubenstein LZ, et al. Interventions for the prevention of falls in older adults: systematic review and meta-analysis of randomised clinical trials. BMJ 2004; 328:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15322/abstract/54\">",
"      Zisberg A, Shadmi E, Sinoff G, et al. Low mobility during hospitalization and functional decline in older adults. J Am Geriatr Soc 2011; 59:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15322/abstract/55\">",
"      Fisher SR, Kuo YF, Graham JE, et al. Early ambulation and length of stay in older adults hospitalized for acute illness. Arch Intern Med 2010; 170:1942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15322/abstract/56\">",
"      Needham DM. Mobilizing patients in the intensive care unit: improving neuromuscular weakness and physical function. JAMA 2008; 300:1685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15322/abstract/57\">",
"      Cumming TB, Thrift AG, Collier JM, et al. Very early mobilization after stroke fast-tracks return to walking: further results from the phase II AVERT randomized controlled trial. Stroke 2011; 42:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15322/abstract/58\">",
"      Kannus P, Siev&auml;nen H, Palvanen M, et al. Prevention of falls and consequent injuries in elderly people. Lancet 2005; 366:1885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15322/abstract/59\">",
"      Haines TP, Bell RA, Varghese PN. Pragmatic, cluster randomized trial of a policy to introduce low-low beds to hospital wards for the prevention of falls and fall injuries. J Am Geriatr Soc 2010; 58:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15322/abstract/60\">",
"      Chelluri L, Grenvik A, Silverman M. Intensive care for critically ill elderly: mortality, costs, and quality of life. Review of the literature. Arch Intern Med 1995; 155:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15322/abstract/61\">",
"      Yu W, Ash AS, Levinsky NG, Moskowitz MA. Intensive care unit use and mortality in the elderly. J Gen Intern Med 2000; 15:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15322/abstract/62\">",
"      Lynn J, Goldstein NE. Advance care planning for fatal chronic illness: avoiding commonplace errors and unwarranted suffering. Ann Intern Med 2003; 138:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15322/abstract/63\">",
"      Landefeld CS, Palmer RM, Kresevic DM, et al. A randomized trial of care in a hospital medical unit especially designed to improve the functional outcomes of acutely ill older patients. N Engl J Med 1995; 332:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15322/abstract/64\">",
"      Jayadevappa R, Bloom BS, Raziano DB, Lavizzo-Mourey R. Dissemination and characteristics of acute care for elders (ACE) units in the United States. Int J Technol Assess Health Care 2003; 19:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15322/abstract/65\">",
"      Bachmann S, Finger C, Huss A, et al. Inpatient rehabilitation specifically designed for geriatric patients: systematic review and meta-analysis of randomised controlled trials. BMJ 2010; 340:c1718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15322/abstract/66\">",
"      Ellis G, Whitehead MA, O'Neill D, et al. Comprehensive geriatric assessment for older adults admitted to hospital. Cochrane Database Syst Rev 2011; :CD006211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15322/abstract/67\">",
"      Coleman EA. Falling through the cracks: challenges and opportunities for improving transitional care for persons with continuous complex care needs. J Am Geriatr Soc 2003; 51:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15322/abstract/68\">",
"      Weissman DE, Meier DE. Identifying patients in need of a palliative care assessment in the hospital setting: a consensus report from the Center to Advance Palliative Care. J Palliat Med 2011; 14:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/61/15322/abstract/69\">",
"      Hansen LO, Young RS, Hinami K, et al. Interventions to reduce 30-day rehospitalization: a systematic review. Ann Intern Med 2011; 155:520.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16283 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-221.10.40.232-BF0A88A09A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_61_15322=[""].join("\n");
var outline_f14_61_15322=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25046879\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25046683\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25046690\">",
"      INCREASED VULNERABILITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H657887\">",
"      PATIENT ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H657914\">",
"      Medication reconciliation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H657921\">",
"      Advance directives",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H657928\">",
"      Social support",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5404484\">",
"      Vaccinations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25046739\">",
"      PREVENTING SPECIFIC ADVERSE OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25046746\">",
"      Functional decline",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31092115\">",
"      Falls",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31092207\">",
"      Delirium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25046760\">",
"      Tethers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H657213\">",
"      Infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31092339\">",
"      Malnutrition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25046781\">",
"      Pressure ulcers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25046788\">",
"      Venous thromboembolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31091992\">",
"      Adverse drug events",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25046802\">",
"      HOSPITAL-WIDE INTERVENTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25046809\">",
"      Multidisciplinary team",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25046830\">",
"      Checklists and order sets",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25046837\">",
"      Early mobilization programs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25046844\">",
"      Safety equipment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12189663\">",
"      SITES OF CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25046851\">",
"      Intensive care in critical illness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27349052\">",
"      Geriatric units",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12189686\">",
"      Alternatives to hospital care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25046865\">",
"      PALLIATIVE CARE/COMFORT-FOCUSED CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25046872\">",
"      DISCHARGE PLANNING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25046879\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/16283\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/16283|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?9/29/9682\" title=\"algorithm 1\">",
"      Assessment and Rx of delirium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/16283|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/21/36178\" title=\"figure 1\">",
"      Homeostenosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/9/44190\" title=\"figure 2\">",
"      Causes of falls",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/16283|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/33/19997\" title=\"table 1\">",
"      Initial functional assessment hosp older adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/13/2269\" title=\"table 2\">",
"      Katz daily living scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/3/44093\" title=\"table 3\">",
"      Lawton daily living scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/0/20494\" title=\"table 4\">",
"      OARS institutional questionnaire",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/53/28510\" title=\"table 5\">",
"      OARS community questionnaire",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/48/1804\" title=\"table 6\">",
"      Confusion assessment method",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/11/1214\" title=\"table 7\">",
"      Drugs that cause or prolong delirium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/35/33340\" title=\"table 8\">",
"      Line infection prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/18/24877\" title=\"table 9\">",
"      Isolation precautions system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/28/14795\" title=\"table 10\">",
"      Hand hygiene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/2/30765\" title=\"table 11\">",
"      Selected high-risk drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/62/31724\" title=\"table 12\">",
"      Palliative care assessment at admission criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/16/37131\" title=\"table 13\">",
"      Primary palliative care assessment components",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/44/15053\" title=\"table 14\">",
"      Discharge checklist",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31017?source=related_link\">",
"      Aspiration pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/22/25962?source=related_link\">",
"      Assessment and management of the acutely agitated or violent adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/18/36137?source=related_link\">",
"      Clostridium difficile in adults: Epidemiology, microbiology, and pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/9/33941?source=related_link\">",
"      Complications of urinary bladder catheters and preventive strategies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43624?source=related_link\">",
"      Comprehensive geriatric assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39081?source=related_link\">",
"      Diagnosis of delirium and confusional states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/0/30730?source=related_link\">",
"      Drug prescribing for older adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/48/11014?source=related_link\">",
"      Emergency airway management in the geriatric patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/51/33592?source=related_link\">",
"      Enteral feeding: Gastric versus post-pyloric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/53/8026?source=related_link\">",
"      Epidemiology of methicillin-resistant Staphylococcus aureus infection in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/57/12183?source=related_link\">",
"      Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27721?source=related_link\">",
"      Epidemiology, prevention and control of vancomycin-resistant enterococci",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44024?source=related_link\">",
"      Ethical issues near the end of life",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/7/32887?source=related_link\">",
"      Ethics in the intensive care unit: Withholding and withdrawing life-support",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/54/32618?source=related_link\">",
"      Evaluation of infection in the older adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/4/22602?source=related_link\">",
"      Falls in older persons: Risk factors and patient evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19658?source=related_link\">",
"      General principles of infection control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/18/38186?source=related_link\">",
"      Geriatric health maintenance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/12/31946?source=related_link\">",
"      Geriatric nutrition: Nutritional issues in older adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/2/12330?source=related_link\">",
"      Hospital discharge",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/8/14473?source=related_link\">",
"      Legal aspects of end of life care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/9/42138?source=related_link\">",
"      Medical care of the nursing home patient in the United States",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/24/38282?source=related_link\">",
"      Normal aging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13831?source=related_link\">",
"      Nutrition support in critically ill patients: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/17/34073?source=related_link\">",
"      Nutrition support in critically ill patients: Enteral nutrition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/16/34050?source=related_link\">",
"      Patient information: Going home from the hospital (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/47/40697?source=related_link\">",
"      Placement and management of urinary bladder catheters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/20/34120?source=related_link\">",
"      Pressure ulcers: Epidemiology, pathogenesis, clinical manifestations, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/57/12184?source=related_link\">",
"      Prevention and control of Clostridium difficile in hospital and institutional settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/33/28185?source=related_link\">",
"      Prevention and treatment of delirium and confusional states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/51/30521?source=related_link\">",
"      Prevention of adverse drug events in hospitals",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/59/31673?source=related_link\">",
"      Prevention of falls in nursing care facilities and the hospital setting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31578?source=related_link\">",
"      Prevention of intravascular catheter-related infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/1/1049?source=related_link\">",
"      Prevention of pressure ulcers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/21/36186?source=related_link\">",
"      Prevention of venous thromboembolic disease in medical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13433?source=related_link\">",
"      Risk factors and prevention of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/24/44422?source=related_link\">",
"      Urinary tract infection associated with urethral catheters",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_61_15323="Irritant patch test reactions";
var content_f14_61_15323=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F57968&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F57968&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Irritant patch test reactions",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Erythematous",
"       </td>",
"       <td>",
"        Characterized by sharp cut-offs at the patch test site. Seen with fragrance mix, carbamate mix.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Follicular",
"       </td>",
"       <td>",
"        Follicular papules as opposed to micro vesicles. Seen with nickel, cobalt.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pustular",
"       </td>",
"       <td>",
"        More common in atopic individuals",
"        <sup>",
"         [1]",
"        </sup>",
"        . Can be seen with metal salts (eg, nickel). Occasionally can be seen with true allergic reactions.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Soap",
"       </td>",
"       <td>",
"        Glazed erythematous appearance. Seen when testing soaps and shampoos.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bullous/necrotic",
"       </td>",
"       <td>",
"        Seen with high concentrations of caustic materials including gasoline, kerosene.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Hjorth N. Diagnostic patch testing. In: Dermatoxicology and pharmacology, Marzulli F, Maibach HI (Eds), John Wiley and Sons, New York 1977. p.344.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_61_15323=[""].join("\n");
var outline_f14_61_15323=null;
var title_f14_61_15324="Bosniak criteria renal cysts";
var content_f14_61_15324=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F67087&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F67087&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Definition of Bosniak classification of cystic renal masses by CT scanning",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"1\" rowspan=\"1\">",
"        Category I - Simple benign cyst with the following features:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hairline thin wall",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Density less than 20 Hounsfield units (similar to water)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Does not contain septa, calcification, or solid components",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Does not enhance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Category II - Cystic lesions with the following features:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A few hairline thin septa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        \"Perceived\" enhancement may be present. There is no measurable enhancement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        Uniformly high attenuation lesions &lt;3 cm that are well marginated and do not enhance fall into this category",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Category IIF - Minimally complicated cysts that do not neatly fall into category II. These lesions are generally well marginated, but have some suspicious features that require follow-up:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        Multiple hairline thin septa or minimal smooth thickening of the wall or septa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        \"Perceived\" enhacement of septa or wall may be present",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thick and nodular calcification of the wall or septa, but no measurable contrast enhancement is present",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Totally intrarenal, nonenhancing, high attenuation lesions &gt;3 cm in diameter fall in this category",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Category III - True indeterminate cystic masses that typically undergo surgical evaluation, although many lesions are benign. These lesions show the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        Thickened irregular or smooth walls or septa in which measurable enhancement is present",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Category IV - These mostly malignant lesions have the following features:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        All category III criteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        Enhancing soft-tissue components adjacent to, but independent of, the wall or septum",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Israel GM, Bosniak MA. An update of the Bosniak Renal Cyst Classification System. Urology 2005; 66:484.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_61_15324=[""].join("\n");
var outline_f14_61_15324=null;
var title_f14_61_15325="Osmoregulation of ADH";
var content_f14_61_15325=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F65195&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F65195&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Osmotic regulation of ADH release and thirst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 436px; height: 266px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Relation between plasma antidiuretic hormone (ADH) concentration and plasma osmolality in normal humans in whom the plasma osmolality was changed by varying the state of hydration. The osmotic threshold for thirst is a few mosmol/kg higher than that for ADH.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Robertson GL, Aycinena P, Zerbe RL. Am J Med 1982; 72:339.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_61_15325=[""].join("\n");
var outline_f14_61_15325=null;
var title_f14_61_15326="Schematic figure demonstrating hd access in parallel with circ";
var content_f14_61_15326=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F63939&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F63939&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Schematic figure demonstrating hemodialysis access in parallel with circulation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 424px; height: 251px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of standard hemodialysis in which flow through the access is in parallel with the systemic circulation. If flow through the access is relatively low, then urea removal is limited because most of the blood is not entering the dialyzer.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_61_15326=[""].join("\n");
var outline_f14_61_15326=null;
var title_f14_61_15327="Autonomic insufficiency";
var content_f14_61_15327=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F62420&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F62420&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Marked hypotension without tachycardia induced by rapid removal of whole blood during recumbency in a patient with idiopathic autonomic insufficiency",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 261px; height: 277px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The blood pressure returned to baseline with replacement of the lost fluid.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From WAgner, HN Jr, J Clin Invest 1957; 36:1319, by copyright permission of the American Society for Clinical Investigation.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_61_15327=[""].join("\n");
var outline_f14_61_15327=null;
